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ABSTRACT OF DISSERTATION 
 
 
 
 
LATEXIN’S ROLE IN REGULATING HEMATOPOIETIC STEM AND 
PROGENITOR CELLS  
 
Previous studies in our lab identified a novel gene, latexin (Lxn), that 
regulates murine hematopoietic stem cells through balancing apoptosis, self-
renewal and proliferation. In these dissertation studies, I performed a series of 
experiments to examine the function of Lxn using a Lxn conventional knockout 
mouse, and characterize Lxn’s role in the presence of hematopoietic stresses 
such as ionizing radiation, cytokines induced-mobilization, and hematopoietic 
malignancy.  
 
The first series of experiments was designed to determine the role of Lxn 
in hematopoiesis under homeostatic conditions. I found that Lxn-/- mice exhibited 
hyperproliferative hematopoiesis, a repopulation advantage and elevated self-
renewal capacity which was intrinsic to the Lxn-/- hematopoietic cells. 
Furthermore, I identified a reduction in apoptotic frequency in Lxn-/- 
hematopoietic progenitors, which may account for the expansion seen in the 
progenitor population.  
 
In a second series of experiments, I discovered a role of Lxn in the radio-
sensitivity of hematopoietic cells. I found that loss of Lxn in mice confers 
resistance to ionizing radiation. Lxn-/- mice showed rapid hematological 
recoveries after radiation exposure at the stem and progenitor cell (HSPC) level. 
The ablation of Lxn hindered irradiation-induced apoptosis which may underlie 
the radiation resistance through regulating hematopoietic recovery.  
 
In a third series of experiments, I studied the interaction of Lxn-/- stem and 
progenitor cells with their microenvironment. Using a granulocyte colony-
stimulating factor-induced mobilization model, I determined that the ability of 
HSPCs to mobilize into the bloodstream was significantly increased in Lxn-/- 
mice. The adhesive properties of hematopoietic cells were compromised in Lxn-/- 
animals. Gene expression studies on progenitor cells identified cell-to-ECM 
interactions were down-regulated upon Lxn deletion, implying the enhanced 
 
 
mobilization efficiency of hematopoietic cells from Lxn-/- mice correlated with 
reduced adhesion of hematopoietic progenitor cells to stroma. 
 
Last, but not least, I performed a series of experiments to study the 
putative tumor suppressor role of Lxn in hematological malignancy. I found that 
Lxn expression was down-regulated in primary tumor and tumor cell lines by 
promoter methylation. Overexpression of Lxn inhibited lymphoma cell growth 
both in vitro and in vivo. Overexpressed Lxn increased apoptosis frequency by 
suppressing the expression of several anti-apoptotic genes, and therefore 
reduced the tumor growth.  
KEYWORDS: Latexin, hyperproliferative hematopoiesis, radio-resistance, cell 
retention, apoptosis 
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CHAPTER 1: INTRODUCTION 
1.1 Hematopoiesis and hematopoietic stem cell 
Hematopoiesis is the developmental process of blood formation. Blood is 
composed of as many as eight specialized blood cell types, including 
granulocytes, lymphocytes, erythrocytes (red blood cells) and thrombocytes 
(platelets). Different cell types perform distinct biological functions, ranging from 
nutrient and oxygen supply, blood coagulation, and pathogen defense. Since 
these blood cells have a limited lifespan, a large pool must be replenished 
continuously. In a healthy adult, approximately 1011-1012 new blood cells are 
produced daily, by a small number of hematopoietic stem cells (~105)(HSCs)1-3.  
HSCs reside in bone marrow (BM) and have the unique capacity to give 
rise to a large population of mature blood cells of various lineages. Much like 
stem cells from other tissues, pluripotent differentiation potential and highly 
conserved self-renewal capacity are common features of HSCs. 1) HSCs reside 
on top of the hematopoietic hierarchy. A small number of HSCs are able to 
rapidly accomplish their regenerative task via the generation of very proliferative 
multi-potent progenitor cells (MPPs). These cells differentiate into lineage-
committed progenitor cells such as common lymphoid progenitor (CLP) and 
common myeloid progenitors (CMP). The lineage committed progenitor cells 
further differentiate in a series of steps to mature blood cells which have no 
differentiation potential (Fig. 1.1). In general, along the hematopoietic hierarchy, 
stem and progenitor cells gradually lose differentiation potential from pluripotent 
2 
to unipotent, and this multi-lineage differentiation potential is one of the hallmarks 
of stem cells. 2) Another unique feature of HSCs is their capacity to self-renewal. 
The self-renewal is defined as: a stem cell produces one daughter cell which 
remains as stem cell, and another daughter cell which has more restricted 
differentiation and proliferative potential. In this way, HSCs maintain the size of 
the stem cell pool, preventing depletion of HSCs by differentiation. 3) Proliferative 
capacity is not a unique feature of HSCs. However, the proliferative nature of 
HSCs may affect other unique features such as in vivo HSC self-renewal and 
differentiation potential 4.  The extensive proliferation history leads to loss of stem 
cell functional quality which known as replicative senescence5. In sum, all three 
features mentioned above are indispensable for HSCs. The intrinsic balance 
between proliferation, differentiation and self-renewal is essential for maintaining 
hematopoietic homeostasis, robustly restoring injured hematopoiesis (blood loss 
or ionizing radiation induced injury), as well as rapidly responding to pathogen 
infection.  
1.2 Stem cell niche 
The hematopoietic stem cell niche is an anatomic location in bone marrow 
where HSCs remain quiescent, self-regenerate, proliferate or differentiate in 
response to various extrinsic cues. The first study that described the possible 
physiological functions of niche cells was conducted in Dr. John Trentin's lab forty 
years ago6, 7. They demonstrated an active role of stromal cells in regulating the 
differentiation of HSCs. In 1978 Schofield expanded the observations of Trentin 
and others and proposed a hypothesis in which HSCs reside in specific 
3 
microenvironments where HSC fate decisions are made8. The microenvironment 
has been termed "niche"6, 7.  In recent years, there have been many studies of 
the HSC niche to identify the cell types that compose the niche and to determine 
the signals that regulate HSC behavior within the niche.  
1.2.1 Endosteal niche and vascular niche 
Previous studies revealed two types of hematopoietic stem cell niches: the 
vascular niche and the endosteal niche (Fig. 1.2). The vascular niche consists of 
endothelial cells lining sinusoidal vessels.  This particular microenvironment has 
been shown to be critical in supporting the differentiation and proliferation of 
short-term HSCs and HSC regeneration after injury9. The endosteal niche is 
located on the inner surface of the bone cavity and is comprised of a 
heterogeneous cell population that includes, endothelial cells, adipocytes, and 
osteoblasts10-14 (Fig. 1.2).  This niche, in general, is primarily associated with a 
capacity to provide signals for HSC quiescence.  The two niches work 
cooperatively in a dynamic process that permits HSCs to migrate from a hypoxic 
endosteal microenvironment, in a relatively inactive state, to sinusoidal vessels, a 
permissive environment that promotes HSC proliferation and differentiation15. 
1.2.2 Cell types in the bone marrow niche 
Amongst the various cell types within the endosteal niche, osteoblasts 
play an important role in reciprocal communication with primitive stem cells16, 17. 
In vivo, HSCs are localized spatially close to osteoblasts16, 18 (Fig. 1.2). Ablation 
of osteoblasts resulted in a significant reduction in the hematopoietic cell 
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population, which indicates a supportive role of osteoblasts in maintaining 
HSCs12. Moreover, other niche components such as neuronal cells and 
adipocytes have also been shown to be involved in regulating the HSC pool. 
Nonmyelinating Schwann cells of autonomic nerves have been shown to be a 
critical determinant in maintaining HSC hibernation by activating latent TGF-
beta13.  Niche adipocytes were discovered as negative regulators of HSCs in a 
study using a lipoatrophic mouse model and pharmacological inhibition of 
adipocyte formation14.  While so many characteristics of the BM niche have been 
defined, the crosstalk among niche cells and stem cells, as well as the 
mechanisms through which the microenvironment regulates HSC fate, requires 
further exploration. 
1.3 Stem Cell Trafficking 
HSC trafficking is believed to be essential for definitive hematopoiesis 
during pre-natal and early post-natal periods. During development, HSCs migrate 
from the aorta-gonad-mesonephros (AGM) region,  to the fetal liver, and finally to 
the BM19. However, HSCs continue to migrate throughout postnatal life. Some 
are continuously in blood circulation under homeostasis, but may migrate back to 
and reside in BM niches, where they hibernate, proliferate or self-renew. This 
two-way commute is central to hematopoietic homeostasis. It is possible that 
stem cell move out of the bone marrow may ferry molecules to and from the 
niche to other tissues and organs throughout the body. 
5 
1.3.1 Mobilization 
The egression of HSCs from the BM into blood circulation is called 
mobilization. During mobilization, HSCs actively move close to sinusoidal vessels, 
pass the vascular endothelial wall, migrate into the bloodstream, and then 
infiltrate into other tissues (e.g. spleen)20.  The release of HSCs from the BM into 
the bloodstream is believed to be a physiological phenomenon for maintaining 
hematopoietic homeostasis through balancing HSC numbers21.  Egress of 
HPSCs into the bloodstream follows circadian rhythms.  Studies showed a 
fluctuation of circulating HPSCs peaks 5 hours after the initiation of light and 
nadirs 5 hours after darkness22-24. After receiving photic stimulation, the circadian 
pacemaker in the central nervous system (CNS) down-regulates the production 
of SDF-1 in its niche24.   With a compromised SDF-1 dependent HSC retention in 
the niche, HSPCs readily enter the circulation24.  
Furthermore, HSC migration is manifested and utilized in clinical practice 
using cytokine exposure.  Mobilization agents such as cyclophosphamide, 5-
fluorouracil, stem cell factor (SCF), stromal derived factor-1 (SDF-1), and 
granulocyte-colony stimulating factor (G-CSF) are used extensively in a clinical 
setting to obtain adequate HSPCs from the transplant donors by pushing large 
numbers of HSPCs into the peripheral circulation 25-29.   
 1.3.2 Homing 
In contrast to mobilization, HSCs also continuously home back to the BM 
niche under homeostasis, or after BM transplantation. The homing of circulating 
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HSCs requires a set of molecular interactions that mediate the sequential 
process of endothelial adhesion, rolling and transmigration through the 
endothelium. Several molecules are involved in these processes, the most 
important ones being adhesion molecules.  
1.3.3 Molecules involved in HSC migration and homing 
Migration and homing are both mediated by adhesion molecules and their 
ligands (Table1.1). Both HSCs and endothelial cells in the niche express 
adhesion molecules.  In the tethering process, P- and E-selectin on endothelial 
cells work co-operatively to bind to P-selectin glycoprotein ligand-1 (PSGL-1, a 
glycoform of CD44 in human) on stem cells and progenitors 30-33.  Once stem cell 
and progenitors are anchored, stromal derived factor-1 (SDF-1) activates 
intergrin by interacting with C-X-C chemokine receptor type-4 (CXCR4), and 
induces HSC transmigration through the vascular endothelial cell wall to the 
niche 34-36.  Very late antigen-4 (VLA-4) and VLA-5, both of which belong to 
intergrin family, interact with adhesion molecules, particularly vascular cell 
adhesion molecule-1 (VCAM-1), and provide rigorous binding 37-39.  Defective 
HSC homing or retention most likely indicates down-regulated expression of 
adhesion molecules, and results in reduced cell-to-cell or cell-to-extracellular 
matrix interaction.   
Additional molecules like small GTPase and hormonal signals have been 
reported to be involved in HSPC homing and mobilization.  Mice defective in R-
Ras (Rac1/Rac2 activator) expression, exhibit decreased BM homing and 
increased responsiveness to G-CSF induced mobilization 40. Cdc42, another 
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small GTPase that mediates adhesion, is activated in aged HSCs 41. Elevated 
levels of cdc42 activity are associated with a decline in HSC retention and 
increased mobilization with advanced age41. Furthermore, Parathyroid hormone 
(PTH) can effectively induce the mobilization of HSPCs, whereas Prostaglandin 
E2 (PGE2) elevates HSC homing efficiency 
42-44.  
1.4 Ionizing radiation toxicity 
Maintaining a stable supply of mature blood cells is essential for nutrient 
supply, pathogen defense and tumor surveillance in hematopoiesis. However, 
this homeostasis can be perturbed by DNA-damaging agent such as ionizing 
radiation. Ionizing radiation is a high-frequency radiation that has very high 
energy and the capacity to remove an electron from an atom. When ionizing 
radiation passes through a cell, its high energy causes intracellular atoms and 
molecules to become excited, or “ionized”. This ionization can break chemical 
bonds, produce free radicals, and damage molecules (e.g. DNA, RNA and 
proteins), which are vital in biological processes45.  
The blood forming-organs, reproductive organs, digestive organs, skin, 
bone and teeth are primary targets of radiation. Among the tissues mentioned 
above, the blood system is most sensitive to radiation due to its high turnover 
rate. In the mouse, after exposure to irradiation, blood cell numbers increase in 
the first several days (overshoot stage), then drop off, and reach a nadir at 3-4 
weeks (nadir stage)46, 47(Fig. 1.3). Subsequently, the number of blood cells 
begins to increase and reaches a plateau at 8 weeks post irradiation (recovery 
stage)46. The recovery stage is the most important period in increasing the 
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survival rate after radiation injury.  
1.4.1 Radiation-induced HSC apoptosis, senescence and tumorigenesis 
After exposure to ionizing radiation, radiation-induced DNA damage 
immediately halts cell cycle progression (cell cycle arrest) (Fig. 1.4). During the 
period of cell cycle arrest, DNA repair machinery is triggered and begins to repair 
the damage. If the repair is unsuccessful, the cells are removed by a 
programmed cell death mechanism (apoptosis). From the studies of the 
response of HSCs to ionizing radiation, beginning during the World War II, it has 
been learned that a majority of HSCs die after radiation exposure by triggering 
apoptosis45, 48. A dose of 4 Gy radiation induced apoptosis in 65% of HSCs (Lin-
Sca-1+c-Kit+ cells), and in 50% of primitive progenitors (Lin-Sca-1-c-Kit+ cells)49, 50.  
In some cells, the cell cycle arrest becomes permanent. These cells lose 
their proliferation capacity and become senescent49. A study on human HSCs 
(CD133+ cells) demonstrated that, even though these cells were successfully 
repaired, their ability to self-renew was permanently damaged49. An increase in 
p16Ink4a expression on HSCs also implies the induction of premature senescence 
in these cells49.  
In some circumstances, apoptosis and senescence do not functionally 
remove all of the damaged cells. A small number of cells survive radiation stress 
with chromosome aberrations (Fig.1.4). These cells are dangerous due to their 
genomic instability, and have potential to result in tumorigenesis in the future. It 
has been previously reported that DNA repair machinery reaches its maximal 
effectiveness after a dose of 0.4~0.5 Gy radiation51, 52. Therefore, high doses of 
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radiation or continuous low doses of radiation can readily induce tumorigenesis. 
In general, a balance between cell proliferation, senescence and 
apoptosis is critical for tissue homeostasis. In this dissertation, I will focus on 
Latexin deficiency induced radio-resistance and its role in regulating apoptosis in 
irradiated HSCs. 
1.5 Identification and quantitation of hematopoietic progenitor and stem 
cells 
Various assays have been established to measure the number and 
functionality of HSCs and their progeny. These assays include in vitro 
phenotyping assays, in vitro clonogenic assays, and in vivo transplantation 
assays, all of which are used to help enhance our understanding of 
hematopoietic progenitor and stem cell biology.  
1.5.1 Flow cytometric phenotyping  
Advances in flow cytometry over the past decades have revealed 
important information on the phenotypes of different hematopoietic cell subsets. 
Combining fluorescently labeled antibodies against cell surface receptors with 
flow cytometric analysis allows for the identification and isolation of progenitor 
and stem cells53, 54.  Although multiple approaches have been developed over the 
years, a common consensus is that HSCs lack lineage markers (antigens that 
expressed on mature granulocytes, macrophages, B and T lymphocytes and red 
blood cells), and express stem cell receptors (such as Sca-1 and c-Kit)54-60. The 
immunophenotypically identified population (Lineage-/ Sca-1+/c-Kit+ cells, also 
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known as LSK cells) is widely accepted as a partially purified HSC fraction in 
which approximately 1 in 20 cells exhibits long-term reconstitution ability56, 61-63.  
In the past decade, several novel HSC marking strategies have been 
developed. CD34 or Flt-3 expression was shown to be associated with a loss of 
primitiveness in the LSK population63-65. Antibodies against CD34 and Flt-3 
further subdivide the LSK population into three populations (LSK/CD34+/Flt-3+ 
cells, LSK/CD34+/Flt-3- cells and LSK/CD34-/Flt-3- cells), each of which possess 
different engraftment and differentiation potentials63-65. One of the most recent 
additions to HSC marking strategies is the application of antibodies against the 
SLAM family of receptors66. SLAM family receptors are a group of trans-
membrane proteins that regulate T lymphocyte development and function66. 
Primitive HSCs are highly enriched in the CD150+/CD48- cell population with 50% 
HSC activity 66, 67, which to date is the highest purity of HSC described by 
phenotypic identification.  
Another HSC isolation strategy relies on the ability of HSC to efflux 
chemical compounds.  Hoechst 33342 is a fluorescent vital dye that binds to DNA 
content in cells68. BM cells stained with Hoechst 33342 and subsequently 
observed at two emission wavelengths (Hoechst Blue and Hoechst Red) 
revealed a small but distinct population of cells that selectively excluded the 
Hoechst 33342 dye. This population was termed the "side population" (SP), and 
is highly enriched in HSCs68. This methodology allows for the selection of HSCs 
based on cellular activity (multi-drug resistance pumps) rather than the 
expression of cell surface phenotypes. 
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Flow cytometric phenotyping of HSCs is considered an effective way of 
identifying stem cells from heterogeneous BM cells. However, the currently used 
stem cell markers are under debate due to the lack of information regarding true 
HSCs functional phenotype. Generally, under unperturbed conditions, there is a 
good correlation between the phenotype and in vivo reconstitution potential of 
HSCs; under stress conditions (aging, chemo/radio therapy or transplantation), 
phenotypic isolation strategies vary in their efficiency in selecting HSCs. 
1.5.2 Colony-forming unit (CFU) assay  
The CFU assay is an informative in vitro assay widely used to detect and 
quantify hematopoietic progenitor cells. In this assay, BM, spleen or peripheral 
blood cells are mixed with methylcellulose-based medium supplied with a 
combination of cytokines, and cultured for one or two weeks69-75. Progenitor cells 
of different lineages form colonies which have distinct morphologies. In this assay, 
each colony is counted and characterized by lineage according to their 
morphologies. Thus, it offers insight into the lineage specificity of cells, rather 
than assessing the functional activity of primitive, pluripotent HSCs. 
1.5.3 Cobblestone-area forming cell (CAFC) assay 
The CAFC assay is an in vitro limiting-dilution assay used to determine the 
frequency of hematopoietic cell subsets in a developmental hierarchy (Fig.1.5)76-
79. A stromal cell layer (e.g. FBMD-1 cells) is pre-seeded and cultured in 96-well 
plates, and allows for in vitro long-term culturing of stem and progenitor cell. After 
the stromal cells reach confluency, bone marrow cells are plated on top of them. 
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Primitive hematopoietic cells migrate beneath the stromal monolayer and form 
cobblestone-areas, a small colony of 10-50 cells. The frequencies of stem and 
progenitor cells are determined weekly by scoring each well for the presence of 
cobblestone-areas over a period of 5 weeks or longer. It has been shown that the 
latency of appearance of a cobblestone area is positively correlated with the 
primitiveness of a hematopoietic cells 76, 80. Thus, cells that form cobblestone-
areas at day 7 to day 21 are considered hematopoietic progenitor cells, and cells 
that form cobblestones at day 28  to day 35 or later are considered more 
primitive stem. It should be noted that cobblestone areas only present for a week 
or less so they aren't counted more than once in successive weeks. A modified 
CAFC assay (adhesion assay) can also be used to detect the interaction 
between hematopoietic cells and stromal cells81.  In this assay, hematopoietic 
cells are plated onto a stromal layer and the hematopoietic cells and stromal cells 
are allowed to interact for 2 ~ 4 hours. The non-adherent cells are then washed 
away, leaving the adherent cells in culture. These adherent cells will form 
cobblestone-areas at later time points. The adhesion assay generally measures 
the adhesive properties of hematopoietic cells and studies the interaction 
between hematopoietic cells and stromal cells.  
The CAFC assay is a reliable approach for measuring the frequency of 
hematopoietic progenitor and stem cells. However, the in vitro culture conditions 
exclude the influence from the systemic cues and does not realistically mimic the 
in vivo microenvironment. Furthermore, the CAFC assay lacks measurement of 
in vivo homing activities; thus the gold standard for stem cell activity remains in 
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vivo repopulation experiments. 
1.5.4 In vivo transplantation 
The definition of HSC relies on the fact that the cell is able to reconstitute 
the entire hematopoietic compartment in a lethally irradiated animal for a long 
period. This definition makes the in vivo transplantation assay the ultimate 
methodology for identifying the activities of HSCs. The first rigorously quantitative 
assay allowing measurement of multi-lineage reconstitution potential in vivo was 
reported by Harrison in 198082, 83. It was a competitive repopulation (CR) assay in 
which support cells with known HSC activity (competitor cells) and a test cell 
population with unknown HSC activity were co-transplanted into lethally 
irradiated recipients (Fig. 1.6A).  The test and competitor cells were from two 
distinct sources, each possessing different cell surface marker isotypes (e.g. 
CD45.1 or CD45.2), so as to enable tracing of cell origins. In CR assays, the 
HSC activity of test cells is assessed by comparing the proportion of test cell-
derived cells to competitor cell-derived cells in a recipient's peripheral blood. 
Theoretically, with equal numbers of cells, test cells and competitive cells 
reconstitute hematopoiesis equally. Thus, any deviation from the 50% 
engraftment efficiency indicates either a competitive advantage or disadvantage. 
CR assays provide information about HSC reconstitution potential as well as the 
competitive capacity. Furthermore, since the competition occurs in a common, in 
vivo environment, extrinsic factors such as cytokines and stroma can be ruled out. 
CR is a powerful assay to measure the multi-lineage reconstitution 
potential of test cells, but in the long run test cells also require self-renewal to 
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maintain hematopoiesis over a lifespan, a function that can't be directly 
measured by CR. A serial transplantation assay, however, allows the 
measurement of the self-renewal capacity by introducing multiple reconstitution 
stresses84, 85. Serial transplantation, as the name implied, is a repetitive 
transplantation in which test cells are transplanted from one host to another for 
several times over what cumulatively amounts to a mouse lifespan or more (Fig. 
1.6B). For the primary transplant, one million test cells (CD45.2 isotype) are 
mixed with an equal number of competitor cells (CD45.1 isotype) and are 
transplanted to lethally irradiated primary recipients. For the secondary transplant, 
ten million recipient cells (from primary recipients) are transplanted into 
secondary recipients. The same regimen is repeated for the tertiary and 
quaternary transplants.  In this way, the self-renewal capacity of the cells will be 
reflected by the variation in engraftment efficiency in the peripheral blood in each 
successive transplanted recipient. 
1.6 Latexin and stem cell 
Latexin contains 222 amino acids, and is the only known 
carboxypeptidase A4 (CPA4) inhibitor in mammalian cells. CPA4 belongs to the 
zinc-dependent metalocarboxypeptidase (MCP) subfamily A/B. Members of this 
family are located in digestive tract, brain, heart, and lung. They participate in 
peptide hormone activities to regulate cell proliferation and differentiation. The 
overall structure of latexin protein consist of two subdomains, each of which 
bears an alpha-helix and a four-strand beta-sheet running anti-parallel86. The two 
subdomains are linked by a third alpha-helix. The hydrophobic contacts 
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established by the two subdomains embrace the enzyme and perform the 
inhibition. Latexin shares no structural or sequence similarity with 
carboxypeptidase inhibitors in other species. However, latexin has a paralogue 
called Tig1 that has up to 30% sequence similarity with latexin. The two genes 
are located adjacently on chromosome 3. TIG1 has been thought as an ancestor 
gene of Lxn, and is a putative tumor suppressor gene. Its expression is 
epigeneticly modified in numerous cancers, including prostate, breast and some 
hematopoietic malignancy87. The Lxn expression is also suppressed in some 
hematopoietic malignancy such as chronic and acute myeloid leukemia, thus 
suggesting a possible role for it in tumorgenesis. 
Latexin was first discovered in rat brain as a region specific marker of the 
lateral neocortex88, 89. In peripheral nervous system, latexin has been reported to 
be involved in pain transmission by studying constitutive Lxn knockout mice. 
Animals that have no latexin in the nervous system showed a retard sensitivity to 
pain90. Lxn is also highly expressed in rat peritoneal mast cells, as well as mouse 
macrophages87, 91, and its expression is further regulated by several pro-
inflammatory stimuli.  
Though latexin has not been reported in neural stem cell compartments, 
our lab recently discovered that latexin is a homeostatic regulator of HSC 
population size in mice92, 93. We used a forward genetic approach, comparing two 
mouse strains, and indentified Lxn as the quantitative trait gene that regulates 
HSC pool size in mice. The HSC number in mice bone marrow is inversely 
related to quantitative Lxn expression level and is regulated through a concert of 
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proliferation, self-renewal and apoptosis. High Lxn expression induces an 
increased apoptosis as well as decreased proliferation and self-renew. Latexin 
acts as a break not only on HSCs, but also in multi-lineage progenitors and 
mature cells in circulation.  
1.7 Experimental goals and significance 
The experimental goal of this dissertation was to study the function of the 
Lxn gene in regulating hematopoietic stem and progenitor cell biology using a 
Lxn deficient mouse as model. Four specific aims were proposed and tested to 
accomplish this goal:1) to study the phenotypes of Lxn deficient mice in 
peripheral blood, spleen and bone marrow and identify the mechanisms 
underlying these phenotypes; 2) to explore Lxn function under genotoxic stress 
using ionizing radiation; 3) to demonstrate the effect of Lxn on HSC migration 
activities and identify the potential target gene(s) of Lxn that regulate HSPC 
mobilization; 4) to overexpress Lxn in B cell lymphoma cells and study the 
potential tumor suppressor role of Lxn in hematological malignancies.  
The Lxn gene has recently been identified as a novel, homeostatic 
regulator of hematopoietic stem and progenitor cells through concerted 
mechanisms of self-renewal and apoptosis, which increase and decrease along 
with Lxn expression levels, respectively. Generally, Lxn acts as an autonomous 
brake on the expansion of the hematopoietic stem and progenitor cell 
populations. Unrestrained cell expansion brings the risk of genomic instability; 
however, finely controlled expansion aids in hematopoietic recovery after 
genotoxic insults such ionizing radiation. To my knowledge, the roles of Lxn in the 
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development of cancer and in response to ionizing radiation have not yet been 
elucidated. Therefore, examining a lymphoma cell line overexpressing Lxn and a 
Lxn deficient mouse models may help to establish novel strategies for treating 
hematologic malignancies, as well as promoting HSPC recovery in patients 
undergoing radiotherapy or following accidental radiation exposure.  
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Figure 1.1 Developmental hierarchy of the hematopoietic system. 
Long-term HSCs, which are pluri-potent, generate short-term HSCs and multi-
potent progenitor (MPP) cells, which are multi-potent. MPP cells differentiate into 
committed progenitor cells (CLP and CMP), which give rise to 8 types of mature 
blood cells in the peripheral blood. This hierarchy pyramid is positively correlated 
with cell population size, but negatively correlated with self-renewal and 
differentiation capacities. 
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Figure 1.2 The endosteal and vascular niches.  
HSCs reside in both endosteal and vascular niches. A variety of cells, including 
endothelial cells, adipocytes, neuronal cells, and osteoblasts, comprise of stem 
cell niche. HSCs localized near osteoblasts in the endosteal niche tend to be 
quiescent, whereas HSCs that mobilize to the vascular niche are active in 
proliferation and differentiation. Schwann cells wrapping the sympathetic nerve 
promote HSC dormancy.  Adipocytes negatively regulate HSC pool size. 
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Table 1.1 Molecules involved in HSC migration and homing.   
Molecules Function Reference 
CXCR4/SDF-1 HSC homing and mobilization 34-36, 94 
CXCR2/GROβ HSC mobilization 95 
PSGL-1/P-selectin or E-
selectin 
HSC homing and adhesion 33, 96 
VLA-4 (CD49d/α4 
integrin)/VCAM-1 
HSC adhesion, homing, 
mobilization and HSC quiescent 
38, 81 
VLA-5 (CD49e/α4 integrin)/ 
VLA-5 receptor 
HSC adhesion and homing 97 
PTH/PPR Induce HSC proliferation, 
homing and mobilization 
43, 44, 98 
PGE2/ PGE2R Proliferation, homing and HSC 
survival 
42 
CD44/Osteopontin  HSC adhesion and homing 17, 32, 99 
Rho GTPase (Cdc42) HSC homing and HSC retention 40-42 
CD26 HSC homing and mobilization 
(negative regulation) 
100, 101 
 
Adhesive molecules and their ligands, small GTPases, and hormones that are 
involved in HSC migration and homing. 
  
21 
 
Figure 1.3 Mouse peripheral blood leukocyte dynamics after 6.5 Gy 
irradiation.  
After exposed to 6.5 Gy gamma irradiation, blood leukocytes increase in the first 
several days (overshot stage), then drop off, and nadir at 3-4 weeks (nadir stage). 
Subsequently, the number of blood cells begins to increase and reaches a 
plateau at 8 weeks post irradiation (recovery stage). 
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Figure 1.4 Radiation-induced apoptosis, senescence and tumorigenesis.  
After exposure to ionizing radiation, radiation-induced DNA damage stops cell 
cycle progression. The DNA repair machinery is then triggered to repair the 
damage. Successfully repaired cells proliferate to repopulate hematopoiesis. 
However, when the repair is unsuccessful, the cells are removed by apoptosis or 
senescence. A small number of cells can survives radiation stress with 
chromosome aberrations, and may cause tumorigenesis in the future. 
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Figure 1.5 Cobblestone-forming cell  (CAFC) assay.  
The stromal layer (e.g. FBMD-1 cells) is pre-seeded and cultured in 96-well 
plates.  After the stromal cells reach confluency, test cells are plated on top of the 
stromal monolayer in a limiting dilutions. Primitive hematopoietic cells (HSCs or 
progenitors) migrate beneath the stromal monolayer and form cobblestone-areas. 
The frequencies of stem and progenitor cells are determined by scoring each 
well weekly for the presence of cobblestone-areas. 
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Figure 1.6 In vivo transplantation. 
(A) In competitive repopulation (CR) assays, 1x106 WBM test cells (CD45.2) are 
mixed with an equal number of competitor cells (CD45.1), and retro-obitally 
injected into lethally irradiated (9 Gy) CD45.1 recipient mice. (B) In serial 
transplantation assays, 1x106 WBM test cells (CD45.2) are mixed with an equal 
number of competitor cells (CD45.1), and retro-obitally injected into CD45.1 
primary recipients. For secondary transplants, 10x106 unfractionated bone 
marrow cells were harvested from primary recipients (CR recipients) 15 or 16 
weeks post transplantation and transplanted into lethally irradiated secondary 
recipients. The same regimen is repeated for tertiary and quaternary transplants.  
A 
B 
25 
CHAPTER 2: Loss of Latexin Confers a Hyperproliferative Hematopoiesis 
and Altered Self-renewal Capacity in Murine Hematopoiesis  
 
2.1 Abstract 
Previous studies in our lab have identified that a novel gene, latexin (Lxn), 
acts endogenously in murine hematopoietic stem cells (HSCs) to negatively 
regulate population size by enhancing apoptosis and decreasing self-renewal 
and proliferation. To further investigate the functionality of Lxn in hematopoiesis, 
we generated a constitutive knock-out mouse model (Lxn-/- mouse). We 
determined that this mouse model exhibited hyperproliferative hematopoiesis 
including bone marrow hypercellularity, splenomegaly with myeloid cell infiltration, 
and peripheral blood leukocytosis. The bone marrow compartment of these 
animals also displays expansion of early progenitor populations. In accord with 
our original findings, both a repopulation advantage and elevated self-renewal 
capacity were observed in competitive repopulation and serial transplantation 
assays in this mouse model. Reciprocal transplantation using lethally irradiated 
Lxn-/- or B6 mice as recipients showed that the repopulation advantage is 
intrinsic to the hematopoietic cells, and not to the microenvironment. Furthermore, 
we found that there is a reduction in apoptotic frequency in hematopoietic 
progenitors, which may account for an enlarged progenitor compartment in the 
bone marrow. These data indicate that loss of Lxn results in hyperproliferative 
hematopoiesis, a competitive growth advantage, and enhanced self-renewal 
capacity, all of which are hematopoietic cell-intrinsic. Microarray studies 
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performed on a purified stem cell population (HSCs) identified Thrombospondin-1 
(Thbs-1) as a potential target of Lxn, and its expression level is down-regulated 
in Lxn-/- stem cells. In future studies, we plan to study downstream signaling 
pathways of Lxn, focusing on Thbs-1. 
2.2 Introduction 
Latexin was first discovered in rat brain as a region specific marker of the 
lateral neocortex88, 89, 102, 103. In the peripheral nervous system, latexin has been 
reported to be involved in pain transmission90. Animals that have no latexin in the 
nervous system showed a delayed sensitivity to pain. Lxn is also highly 
expressed in rat peritoneal mast cells, and mouse macrophages, and is 
differentially expressed along the hematopoietic hierarchy with the highest levels 
in the  most primitive stem cells91-93.  Our lab used a forward genetic approach, 
comparing two mouse strains, to indentify Lxn as the quantitative trait gene that 
regulates variation in HSC pool size in the mice92, 93. The HSC number in mice 
bone marrow is inversely correlated to quantitative Lxn expression level and is 
regulated through concerted effects on proliferation, self-renewal and apoptosis92, 
93. High Lxn expression induces increased apoptosis as well as decreased 
proliferation and self-renewal, and vice versa.  
The Latexin protein contains 222 amino acids, and is the only known zinc-
finger metallocarboxypeptidase inhibitor in mammalian cells86, 104, 105. However, it 
shares no structural or sequence similarity with carboxypeptidase inhibitors in 
other species. Lxn has a paralogue called tazarotene-induced gene1 (Tig-1), 
which is a putative tumor suppressor gene87, 106. To test the hypothesis that Lxn 
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is a putative tumor suppressor gene like Tig-1, we studied Lxn function in 
hematopoietic malignancy. We found that Lxn expression is highly down-
regulated in a extensive list of leukemia and lymphoma cancers through the 
mechanism of promoter hypermethylation107 (As seen in Chapter 5). Restoring 
the expression of Lxn inhibits tumor growth in vitro and in vivo by enhancing 
apoptosis in tumor cells. 
For these studies, we generated a Lxn constitutive knock-out mouse to 
study the its function in hematopoieisis. We found that Lxn-/- mice exhibited 
hyperproliferative hematopoiesis, a cell-autonomous repopulation advantage and 
elevated self-renewal. A reduced apoptotic frequency in progenitors was found in 
Lxn-/- BM cells, which may account for the enlarged progenitor population. Thbs-
1, which expression was down-regulated in Lxn-/- stem and progenitor cells, was 
identified as a potential target of Lxn.  
2.3 Methods 
2.3.1 Animals 
C57BL/6 mice (B6) (8-16 weeks) and B6.SJL/BoyJ (CD45.1) recipient 
mice (8-16 weeks) were purchased from The Jackson Laboratory (Bar Harbor, 
ME). Latexin constitutive knockout mice were generated by Taconic/Artemis 
(Germantown, NY) and used at a young age (8-16 weeks).  All animals were 
housed in the animal facilities of the University of Kentucky under pathogen-free 
conditions according to NIH-mandated guidelines for animal welfare. They were 
fed with food and water ad libitum. 
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2.3.2 Generation of Lxn deficient mouse 
Latexin constitutive knockout mice were commercially generated under 
contract to Taconic/Artemis (Germantown, NY) and used at young age (8-16 
weeks). The knock-out strategy is described in Results. 
2.3.3 Peripheral blood cell count 
Animals were anesthetized with isoflurane from Butler Animal Health 
Supply (Dublin, OH).  Peripheral blood was collected from retro-orbital venous 
plexus into EDTA-coated microtainer from Becton, Dickinson and Company 
(Franklin lakes, NJ).  Circulating leukocytes, erythrocytes and platelets were 
counted by analyzing 20 ul of blood using a Hemavet 950 from Drew Scientific 
(Dallas, TX). 
2.3.4 Hematopoietic cell identification and isolation 
Bone marrow (BM) cells were flushed from the femora and tibiae into 
Hanks balanced salt solution (HBSS) with 2% fetal bovine serum (FBS)(both 
from Life Technologies, Carlsbad, CA). Progenitor cells were discriminated from 
stem cells by the lack of cell surface antigens characteristic of cells committed to 
individual lineages.  Antibodies against these antigens included CD5 and CD8a, 
B220, Mac-1, Gr-1, and Ter119 were biotinylated. Strepavidin secondary antibody 
was used to detect lineage negative cells. To further purify primitive stem cells, 
stem cell markers Sca-1 and c-Kit, as well as CD34 and Flt3 were incorporated 
into the staining procedure. Phenotypes of purified stem cells are lineage-, c-Kit+, 
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Sca-1+, CD34-, and Flt3-. Lineage-committed progenitor cells, including common 
myeloid progenitor (CMP), granulocyte/monocyte progenitor (GMP), 
megakaryocyte/erythroid progenitor (MEP) and Common lymphoid progenitor 
(CLP), were identified by the markers FcgR, IL7R, CD34 and Flt3. The isolation 
strategy is shown in Fig. 2.2A. Dead cells were excluded by propidium iodide (PI) 
selection that stains exposed double-strand DNA. All monoclonal antibodies were 
purchased from eBioscience (San Diego, CA), Biolegend (San Diego, CA), or BD 
pharmingen (San Jose, CA). 
2.3.5 Cell Analysis and Sorting 
BM cells were analyzed and sorted on a FacsAria II flow cytometer 
(Becton Dickinson, Franklin Lakes, NJ). Cells were sorted into phosphate 
buffered saline (PBS) containing 0.5% FBS for further use. Each experimental 
group was sorted independently. Flow cytometry and FACS data were analyzed 
using FlowJo software (Tree star, Ashland, OR). 
2.3.6 Cell cycle and proliferation analysis 
Cell cycle analysis was performed using Ki-67 and 7AAD. BM cells were 
harvested and stained as described above, and then fixed and permeabIlized 
using the Fix and Perm kit from Invitrogen (Camarillo, CA). Nuclear staining of Ki-
67 was performed using the fluorochrome-conjugated anti-mouse Ki-67 antibody 
from BD pharmingen (San Jose, CA).  
In vivo 5-bromo-2-deoxyuridine (BrdU) incorporation was used to 
enumerate proliferative cells. For immediate incorporation, mice were injected 
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introperitoneally with BrdU (1 mg/kg of body weight) and bone marrow was 
harvested 1 hr later for measurement of BrdU incorporation into recently 
synthesized DNA. For long-term incorporation, BrdU (BD Pharmingen, San Jose, 
CA) was administered at a concentration of 0.5 mg/mL in drinking water that was 
changed every 3 days. BM cells were harvested at 1hr (short term), 3 days and 5 
days (long term) after incorporation, then labeled with a cocktail of HSC cell 
markers (CD5, CD8a, B220, Mac-1, Gr-1, Ter119, c-Kit+, Sca-1+, CD34-, and Flt3-
). Subsequent co-labeling with BrdU and HSC cell markers enabled the 
determination of cell proliferative status in different progenitor and stem cell 
populations.  
2.3.7 Apoptosis analysis 
BM cells were prepared and immuno-fluorescently stained as described 
above. The fluorochrome-conjugated apoptotic marker, Annexin V, along with 
DNA dye, 7-AAD, (both from BD Pharmingen, San Jose, CA) was used to identify 
apoptotic and necrotic cells. Stained cells from Lxn-/- animals and B6 animals 
were analyzed by flow cytometer.  
2.3.8 Colony forming cell (CFC) assay 
Methylcellulose-based culture media was pre-made with Complete 
MethoCult Media (Stem Cell Technologies, Vancouver, Canada) containing 
cytokines including stem cell factor (SCF), IL-3 and IL-6.  For this assay, 1 x 104 
whole BM cells in 100 µL HBSS were thoroughly admixed with 1 mL complete 
MethoCult media, plated into 6-well petri-dish and incubated at 37°C. Individual 
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well of triplicates were scanned on day 7 and 14 to identify relative distribution 
and formation of lineage specified colonies.  
2.3.9 Cobblestone Area Forming Cell (CAFC) Assay  
A monolayer of FBMD-1 stromal feeder cells was seeded in 96-well tissue 
culture-treated plates. After 7 to 10 days (when feeder cells grew confluent), 
wells were seeded at doses of 333, 1000, 3000, 9000, 27000 or 81000 whole BM 
(erythrocyte depleted; see below) cells from Lxn-/- or B6 mice. Individual wells 
were screened at days 7, 14, 21, 28, 35, 42, and 49 for the presence of 
cobblestone areas. The CAFC media (IMDM, supplemented with 20% of horse 
serum and 1 x 10-5 M hydrocortisone) was changed weekly.  
2.3.10 BM transplantation  
In competitive repopulation (CR) assays, 1x106 WBM cells from Lxn-/- 
mice or B6 test cells (both CD45.2) were mixed with an equal number of 
competitor cells (CD45.1) and retro-obitally injected into lethally irradiated (9 Gy) 
B6.SJL/BoyJ CD45.1 recipient mice. Recipients were bled from the retro-orbital 
sinus at 5, 10 and 15 or 16 weeks post transplantation to test engraftment 
efficiency. Erythrocytes were depleted by hypotonic lysis using NH4Cl. The 
leukocytes were stained in triplicate with fluorescent-conjugated monoclonal anti-
CD45.2 and anti-CD45.1 antibodies, as well as B220, Thy1, Mac-1 and Gr-1 
lineage markers (BD pharmingen, San Jose, CA). Samples were analyzed using 
a FACScan instrument (Becton-Dickinson Immunocytometry Systems,). 
For serial transplantation, in primary transplants, one million test cells 
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(CD45.2 isotype) are mixed with an equal number of competitor cells (CD45.1 
isotype) and then transplanted into lethally irradiated primary recipients. In 
secondary transplants, 10x106 unfractionated bone marrow cells were harvested 
from primary recipients (15 or 16 weeks post transplantation) and transplanted 
cells into lethally irradiated secondary recipients. The same regimen was 
repeated for tertiary transplantation. At each transplant, PB and BM cells were 
analyzed as described above. The competitive advantage and self-renewal 
capacity of HSCs was analyzed by comparing the percentage of Lxn-/--derived or 
B6-derived cells at each round of transplantation. 
In reciprocal transplantation, 5x106 unfractionated bone marrow cells 
(B6.SJL/BoyJ, CD45.1) were transplanted into either B6 or Lxn-/- recipients (both 
are CD45.2). At the 5, 10 and 15 weeks post transplantation, PB and BM cells 
were analyzed as described above. The microenvironmental effects were 
analyzed by assessing how well the recipient genotype facilitated engraftment 
efficiency. 
2.3.11 Western blot 
For detecting Lxn and Gfm-1 proteins, total protein was extracted from BM, 
spleen, liver and brain using protein lysis buffer containing a protease inhibitor 
cocktail. Samples were subjected to denaturing PAGE (Novex, 10% Bis-Tris gel), 
and electrotransferred to Immunobilon-P membranes (Millipore), which were 
subsequently blocked and probed with anti-Gfm-1 (Abcam, Cambridge, MA) or 
anti-latexin primary antibody. Primary antibodies were detected with 
phosphatase–conjugated secondary antibodies (Santa Cruz Biotechnology) and 
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electrochemifluorescent (ECF) reagent (Pharmacia Biotech) according to the 
manufacturer's instructions. The membrane was scanned and bands were 
detected and analyzed using a Molecular Dynamics STORM 860 system and 
Imagequant Software. The polyclonal IgG rabbit antibody against latexin was 
generated from the Lxn-specific amino acid sequence CKHNSRLPKEGQAE at 
the C terminus and was produced by Bethyl Laboratories (Montgomery, TX).  
After the detection of Gfm-1/Lxn antibodies, membranes were stripped in 
40% methanol and a buffer containing 100 mM -mercaptoethanol, 2% SDS and 
62.4 mM Tris-HCl. The stripped membranes was reprobed with antibody to -
actin (Santa Cruz Biotechnology) and detected as described above. 
2.3.12 RNA isolation and quantification 
RNA for qRT-PCR was purified using RNeasy Mini Kit (Qiagen, 
Germantown, MD). Total RNA was reverse transcribed with High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, Foster City, CA). Predesigned 
Taqman real-time primer/probes sets for Thbs-1 (Applied Biosystems, Foster City, 
CA) were obtained and PCR was performed using TaqMan Universal Master Mix 
(Applied Biosystems, Foster City, CA) on a ABI7500 Real-Time PCR system 
(Applied Biosystems, Foster City, CA). Expression levels were normalized to 
Gapdh and compared with the ΔΔ threshold cycle method. 
2.3.13 Microarray analysis 
Microarray experiments were performed on fresh BM Multipotent 
progenitor cells (LSK/CD34+/Flt-3+) obtained from three wild type and three Lxn-/- 
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biological samples (each of which was pooled from more than 10 individual 
animals) using Affymetrix Gene Chip MoGene-1_0-st-v1 Arrays (Santa Clara, 
CA). Microarray data were normalized based on the RMA method. To identify 
differentially expressed genes comparing B6 versus Lxn-/- mice, we used the 
limma package in R/Bioconductor and a p-value<0.01 was used as the cutoff to 
select a list of candidate genes. 
2.3.14 Statistics 
Statistical significance between means was determined by a two-way 
Student t test.   
2.4 Results 
2.4.1 Generation of Lxn deficient mouse model 
From previous studies, we learned that Lxn acts as negative regulator of 
HSC population size through balancing proliferation, apoptosis and self-renewal. 
To further explore the in vivo roles of Lxn, we generated Lxn deficient (Lxn-/-) 
mice using a gene targeting method (Fig. 2.1A). The mouse Lxn gene contains 
six exons. A gene targeting construct to flank a region of exon 2-4 by LoxP sites. 
Exons 2-4 were removed after in vivo Cre-mediated deletion in targeted allele. 
Lxn-/- mice appear normal, are produced at the normal Mendelian ratio, and 
show no obvious abnormalities in development with either males or females. 
The Lxn gene is embedded in the intron of another gene, G-elongation 
factor, mitochondrial 1(Gfm1), in the opposite orientation. The deletion of Lxn 
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exons 2-4 resulted in the deletion of a portion of Gfm-1 intron 13. To test the 
absence of latexin protein and the integrity of Gfm-1 protein, we used western 
blot and antibodies against Lxn and Gfm-1 protein. The results revealed that 
latexin protein is not expressed in the BM, spleen, liver and brain of Lxn−/− mice, 
and Gfm-1 expression is intact in Lxn-/- mice, as in B6 wild type mice (Fig. 2.1B).  
2.4.2 Loss of Lxn leads to hyperproliferative hematopoiesis in Lxn-/- mice 
To investigate the function of Lxn and its effect on hematopoiesis, we 
examined the spleen, peripheral blood and bone marrow in Lxn-/- mice. Lxn-/- 
mice showed splenomegaly (Fig. 2.2A) with a significant increase in spleen 
weight due to the expansion of red pulp. We also found an increase in Mac-1/Gr-
1 positive monocytes and granulocytes in the spleen, suggesting monocyte and 
granulocyte infiltration into Lxn-/- spleens (Fig. 2.2B). In the peripheral blood of 
Lxn-/- mice, we found a significant increase in white blood cells (WBCs) and 
platelets (Fig. 2.2C) compared to wild type animals. Amongst WBC subtypes, 
absolute numbers of neutrophils and lymphocytes were increased by 
approximately 50% in Lxn-/- mice, whereas monocytes were increased almost 
100%. (Fig. 2.2C). However, despite the observation of increased absolute 
numbers of granulocytes, lymphocytes and platelets, analysis of lineage 
contributions in PB indicated a lineage skewing that favored lymphoid-lineage 
cells, especially B lymphocytes (Fig. 2.8). Furthermore, the bone marrow of Lxn-
/- mice was hypercellular with a 20% increase in the numbers of mononucleated 
cells (Fig. 2.3B) in femurs. Together, these findings, which include splenomegaly, 
leukocytosis and hypercellular bone marrow, demonstrate that Lxn-/- mice 
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develop hyperproliferative hematopoiesis in both PB and BM. 
2.4.3 Loss of Lxn induces hyperproliferative hematopoiesis phenotype through 
dysregulating progenitor and stem cells 
Next we examined the progenitor and stem cell compartments in the BM 
using both flow cytometry and functional assays. We found that the absolute 
numbers of common lymphoid progenitors (CLPs), common myeloid progenitors 
(CMPs) and granulocyte-monocyte progenitors (GMPs) were significantly 
increased (up to 50 %) in Lxn-/- mice compared to their wild type counterparts 
(Fig. 2.3D)(Phenotypic isolation strategy shown in Fig. 2.3A). The 
megakaryocyte-erythrocyte progenitors (MEP) were increased in Lxn-/- mice, but 
did not reach statistical level of significance (Fig. 2.3D). Further, we observed 50% 
expansion of lineage-cKit+Sca-1+ (LSK) cells in Lxn-/- mice. This expansion was 
due to an increase (~100%) in the multipotent progenitor (MPP) population. The 
absolute numbers of phenotypic short-term HSCs (ST-HSCs) and Long-term 
HSCs (LT-HSCs) remained static (Fig. 2.3E). The colony-forming cell unit (CFU) 
and cobblestone-area forming cell (CAFC) assays are two classical in vitro 
experiments to measure the functional capacity of progenitor and stem cells. 
Here we used both to determine the effect of Lxn on hematopoietic cell functional 
capacity. An increased number of day 14 colony-forming cells per 104 BM cells 
was observed in Lxn-/- mice compare to B6 mice (Fig. 2.4A). These data 
demonstrated that there were increased numbers of progenitors in the BM of 
Lxn-/-, consistent with our flow cytometric data. CAFC assays revealed 
significantly more day 35 cobblestones in Lxn-/- animals (Fig. 2.4B). The cells 
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formed day 35 cobblestones in CAFC assays are commonly considered as stem 
cells. In our results, the increased day 35 cobblestones indicated up-regulated 
HSC numbers in Lxn-/- animals. However, the competitive repopulation unit 
(CRU) assay, the gold standard in numerating the HSC number, found no 
difference between the HSC numbers in Lxn-/- and B6 mice (data not shown). 
Therefore, we considered that there were increased numbers of cells only in the 
progenitor population, not but in the most primitive stem cell population. 
2.4.4 Loss of Lxn confers a significant competitive advantage and self-renewal 
capacity to HSCs. 
To further investigate the effect of Lxn knockout, we performed BM 
competitive repopulation assay and serial transplantation experiments. For the 
competitive repopulation experiments, one million BM cells from either wild type 
B6 mice (CD45.2 isotype) or Lxn-/- mice (CD45.2 isotype), along with same 
number of competitor B6.SJL cells (CD45.1 isotype), were transplanted into 
lethally-irradiated recipients (Fig. 2.9A). Fifteen weeks after transplantation, 
granulocytes (Mac-1+/Gr-1+ cells) and B lymphocytes (B220+ cells) were 
enriched in the PB of Lxn-/- mice compared to the ratio used for transplantation 
(1:1) (Fig. 2.4F). Over time, the proportion of Lxn-/- donor-derived cells gradually 
increased in PB, BM and BM LSK cells (Fig. 2.4C, D and E), suggesting a 
competitive advantage of Lxn-/- cells. 
We then tested the self-renewal capacity of Lxn-/- HSCs in serial 
transplant experiments in which they, along with B6.SJL (CD45.1 isotype) BM 
cells, competed for engraftment in lethally irradiated B6.SJL recipients. For the 
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primary transplant, one million test cells (CD45.2 isotype) were mixed with an 
equal number of competitor cells (CD45.1 isotype) and were transplanted into 
lethally irradiated primary recipients. For the secondary transplant, ten million 
recipient cells (from primary recipients) were transplanted into secondary 
recipients. The same regimen was repeated for the tertiary transplants (Fig. 2.9B). 
At each transplant, PB, BM and BM LSK cells were analyzed. The percentages 
of Lxn-/- and B6 cells in each compartment were compared. Lxn-/- stem cells 
showed a sustained competitive advantage in each population (BM and BM LSK 
cells) at primary, secondary and tertiary transplants (Fig. 2.5B and C), 
demonstrating that they retained self-renewal capacity under replicative stresses. 
At the tertiary transplant, the number of Lxn-/- donor-derived BM and LSK cells 
remained high (Fig. 2.5C), whereas the number of their progeny  (PB cells) 
dropped to the same level as that of the wild type. This observation may be 
explained by replicative senescence. 
The BM microenvironment influences HSC lineage fate decisions and 
HSC function. The proliferative hematopoiesis can arise from hematopoietic cells 
themselves. It also can be induced by cues from the microenvironment 
endogenously. In previous studies, we observed that hyperproliferative 
hematopoiesis in Lxn-/- mice is transplantable, indicating this phenotype is at 
least partially cell intrinsic. To investigate the extrinsic effects, we performed 
reciprocal transplants (Fig. 2.9C). Congenic wild-type cells (CD45.1 isotype) 
were transplanted into lethally irradiated Lxn-/- or B6 recipient mice. By 5, 10 and 
15 weeks post transplantation, there was no difference in donor-derived 
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leukocytes in PB between the two groups (Fig. 2.5D). Thus, the proliferative 
hematopoiesis observed in Lxn-/- mice is cell-autonomous, and was not induced 
by the Lxn deficient microenvironment. However, the donor-derived myeloid cells 
were significantly suppressed in Lxn-/- recipients, indicating Lxn-/- 
microenvironment has an influence on lineage preference (Fig. 2.5E). Skewing 
toward the myeloid lineage conceals the myelo-proliferation in Lxn-/- mice, 
explaining the significantly increased myeloid cells in transplants of Lxn-/- BM 
cells (Fig. 2.4F), but not in Lxn-/- mice (Fig. 2.8). 
Ultimately, CR, serial transplantation and reciprocal transplantation 
experiments showed that loss of Lxn confers a competitive advantage and 
increased self-renewal capacity to hematopoietic cells at the level of the HSC 
(cell intrinsic). 
2.4.5 Decreased apoptosis frequency in Lxn-/- HSPCs may account for 
enlarged progenitor and stem cell compartments. 
As previously reported, Lxn expression positively regulates apoptosis but 
negatively influences proliferation and self-renewal (and vice versa)92, 93. In this 
study, we found a proliferative hematopoiesis caused by dysregulation at the 
level of the MPP. To explore the mechanism underlying the phenotype, we 
studied cell cycle, proliferation, and apoptosis in Lxn-/- hematopoietic cells. BrdU 
labeling and Ki-67 staining of hematopoietic cells showed no significant 
difference in cell cycle and proliferation status between Lxn-/- and B6 animals 
(Fig. 2.10A, B and C). We found decreased numbers of PI-/Annexin V+ cells in 
MPP, ST-HSC and LT-HSC populations in Lxn-/- mice compared to B6 mice (Fig. 
40 
2.6A and B), suggesting that Lxn positively regulates apoptosis in stem and 
progenitor cells. The apoptotic frequency of Lxn-/- cells was reduced the most in 
the MPP population (50% increase). Thus, the observed MPP expansion may be 
caused by a decreased rate of apoptosis.  
2.4.6 Functional categories enriched in the differentially expressed genes in 
Lxn-/- MPP cells. 
To gain insight into the molecular mechanisms by which loss of Lxn 
induced the various hematopoietic phenotypes, we examined the gene 
expression profiles. Microarray experiments were performed in LSK/CD34+/Flt-3+ 
BM cells obtained from B6 and Lxn-/- mice using Affymetrix Gene Chip MoGene-
1_0-st-v1 arrays. Using a significance threshold of 0.01, we identified 650 genes 
that were differentially expressed between Lxn-/- and B6 LSK/CD34+/Flt-3+ cells. 
Some of the most highly under-expressed or expressed genes were identified 
(Tab. 2.1). Thbs-1 is one of most highly down-regulated genes, Its expression 
level was decreased 4-fold in Lxn-/- hematopoietic multi-potent progenitor 
populations (data not shown). To study Thbs-1 as the target gene regulated by 
Lxn, we tested Thbs-1 expression at the level of transcript (using quantitative 
real-time PCR) in hematopoietic cells. Consistent with microarray results, the Q-
PCR analysis revealed that thbs-1 expression gradually decreased along 
hematopoietic differentiation hierarchy, in parallel with Lxn expression (Fig. 2.7). 
We also examined the Thbs-1 expression level in FDC-P1 cells (a hematopoietic 
stem and progenitor cell line) overexpressing Lxn. The results showed that 
ectopic Lxn up-regulated Thbs-1 expression in vitro, indicating that Lxn is an up-
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stream regulator of Thbs-1 (data not shown). However, the mechanism 
underlying Lxn regulation of Thbs-1 expression has not been elucidated in these 
studies. The next logic step for this research will be study Lxn signaling pathway 
focusing on Thbs-1. 
2.5 Discussion 
In these studies, we found that Lxn-/- mice exhibited hyperproliferative 
hematopoiesis, including bone marrow hypercellularity, splenomegaly with 
myeloid cell infiltration, and peripheral blood leukocytosis, which may caused by 
decreased apoptosis. We also showed a cell-autonomous repopulation 
advantage and elevated self-renewal capacity in Lxn-/- mice, indicating that loss 
of Lxn leads to enhanced stem cell function. Lxn has been identified as a novel 
regulator of hematopoietic stem cell population size through balancing apoptosis, 
proliferation and self-renewal93. Congenic mice expressing low expression levels 
of Lxn exhibited decreased apoptosis activities, but increased self-renewal 
capacity and HSC frequency in BM cells. In our studies, loss of Lxn induced 
decreased apoptotic activities, increased self-renewal capacity, and increased 
day 35 cobblestones in CAFC assay, which is consistent with previous findings. 
However, competitive repopulation unit (CRU) experiments do not show any 
alteration in functional HSC frequencies in Lxn-/- mice compared to B6 mice 
(data not shown), supported by the results that the numbers of phenotypically 
identified long-term and short-term HSCs in Lxn-/- mice were not altered 
compared to B6 mice. This may be due to the fact that the effective window of 
Lxn activities is limited and/or its effect in regulating HSC population size is dose-
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dependent. Relative high or low levels of Lxn expression may regulate the HSC 
population size, however, the absence of Lxn during hematopoiesis may not 
influence the number, but the other functional properties of HSCs. The 
inconsistency between the CRU and CAFC results may be explained by the 
controversy of the correlation between the days of appearance of a cobblestone 
area and the primitiveness of the stem cell. The phenotypic HSCs (Lin-Sca-1+c-
Kit+CD34-Flt-3-CD150+) can form cobblestones continuously from day 28 to day 
64 after plating (unpublished data). Therefore, the frequency of day 35 
cobblestones does not represent the accurate numbers of HSC, and leaves the 
gold standard in enumerating HSCs with the CRU assay. 
The hematopoietic stem cell niche is an anatomic location in the BM 
where HSCs remain quiescent, self-regenerate, proliferate or differentiate in 
response to various extrinsic cues. Direct interactions between stromal cells and 
stem cells, or indirect interactions through cytokines secreted by stromal cells are 
critical for stem cell fate decisions. Proliferative hematopoiesis is generally 
considered to be intrinsic to hematopoietic cells. However, recent studies have 
provided support for the role of the microenvironment in coordinating many 
aspects of  hematopoietic biology. Studies utilizing transgenic mice such as RAR 
gamma and Nf1 have demonstrated that microenvironmental cues may influence 
stem cell self-renewal capacity, alter lineage distribution, and induce proliferative 
hematopoiesis108, 109. Given that the microenvironment is known to be an 
important regulator of stem cell fate, it is reasonable to speculate that the niche 
cells could induce the phenotypes observed in Lxn-/- mice model. In this study, 
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we demonstrated a proliferative hematopoiesis, which is transplantable and 
therefore cell-intrinsic. Under homeostasis, Lxn-/- mice showed increased 
leukocytes and platelets in PB as well as increased cellularity and an expanded 
HSPC population in the BM. After transplanting Lxn-/- or B6 BM cells with an 
equal number of competitor cells, Lxn-/- cells showed better engraftment 
efficiency compared to B6 cells (60% recipient engraftment for Lxn-/- cells vs. 40% 
engraftment in recipient receiving B6 cells). Further, hematopoiesis in Lxn-/- mice 
showed lineage skewing toward the B cell lymphoid lineage. We also observed 
this phenotype in recipients transplanted with Lxn-/- BM cells. Although the 
transplantation studies show that the proliferative hematopoiesis and lineage 
skewing are cell-autonomous, these data cannot rule out the effects of extrinsic 
factors. We performed reciprocal transplants to clarify this issue. Results from 
reciprocal transplants showed no significant difference of engraftment efficiency 
was induced by the loss of Lxn in the microenvironment. However, there was a 
modification in lineage distribution. Myeloid lineage cells were significantly 
decreased in the Lxn-/- microenvironment, whereas Lxn-/- cell showed a slight 
increase in the numbers in the background microenvironment. These 
observations indicate that loss of Lxn in the stem cell niche does not influence 
the competitive advantage, but may modify the lineage distribution to favor 
lymphoid cells. 
The positive correlation between Lxn expression and apoptotic activity in 
hematopoietic cells has been previously reported93, 107. Mutations in other pro-
apoptotic genes such as p53 are found in hematopoietic malignancies and, in 
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many cases, are thought to be the initiating mutations that generate pre-leukemic 
cell at HSC level. Apoptosis is an intrinsic mechanism which scavenges pre-
leukemic cells and protects chromosome integrity. The mutations that generate 
pre-leukemic cells are thought to escape apoptosis. Overexpression of Lxn in 
tumor cells suppressed tumor growth both in vitro and in vivo, demonstrating a 
pro-apoptotic role of Lxn (as seen in Chapter 5). Further, we found decreased 
apoptotic frequency in Lxn-/- cells, which may underlie the proliferative 
hematopoiesis we observed in the BM of Lxn-/- mice. Will this proliferative 
hematopoiesis lead to hematological malignancies? To answer this question, we 
examined the cells after a series of transplantation. In primary transplants, Lxn-/- 
derived BM and LSK cells were approximately 100% more than B6 derived BM 
and LSK cells. These advantages persisted in secondary and tertiary transplants, 
indicating an advanced self-renewal capacity in Lxn-/- HSCs. On the other hand, 
Lxn-/- derived PB cells in recipients were 50% more than B6 derived PB cells. 
However, this trend did not persist upon tertiary transplants. Instead of taking 
over the entire hematopoiesis in tertiary transplant recipients, the Lxn-/- derived 
PB cells showed no significant difference compared to B6 derived PB cells, 
indicating a reduction in differentiation from BM cell to PB cell that may due to 
replicative senescence, or a physiological optimum in which Lxn-/- transplanted 
cells maintained a maximal occupation in donor’s hematopoiesis through self- 
(apoptosis) or systemic regulation (phagocytosis)110. In another series of 
experiments (Chapter 3), we treated Lxn-/- and B6 mice with 6.5 Gy sub-lethal 
doses of radiation and monitored their hematopoietic recovery up to 90 days post 
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radiation. No significant difference has been identified in PB leukocyte counts 
and BM cellularity in irradiated Lxn-/- mice compared to B6 mice. These 
observations imply that the loss of Lxn will not induce tumorigenesis in 
hematopoietic cells. However, this hypothesis is not definitive because no 
pathological examination has been performed on Lxn-/- BM. A hyperproliferative 
hematopoiesis can be induced by increased proliferation as well. In previous 
studies performed on congenic mice, we found that proliferative activities are 
negatively correlated with Lxn expression level93. However, we did not observe 
any changes in proliferation and cell cycling in Lxn knockout mice, or in tumor 
cells overexpressing Lxn. The consensus congenic interval on chromosome 3 
contains approximately 30 Mb and is composed of a large number of genes. It is 
possible that the proliferation trait linked to this congenic interval may be 
accounted for by genes other than Lxn.  
In these studies we have shown that the proliferative hematopoiesis in 
Lxn-/- cells is accounted by the increase in MPP populations, in which the cell 
population expanded the most. So we performed microarray experiments on 
purified MPP populations from Lxn-/- and B6 mice. We identified Thbs-1, as a 
putative target for Lxn using microarray analysis; Loss of Lxn significantly down-
regulated the expression of Thbs-1. Thbs-1 is a glycoprotein that mediates the 
cell-to-cell and cell-to-ECM interactions. It plays a very important role in the niche 
in binding to various extracellular matrix ligands such as fibrinogen, fibronectin, 
collagens, TGF- , some matrix metalloproteinases, and to cell surface receptors 
including CD36 and CD47111, 112. Loss of Thbs-1 in mouse model showed a radio 
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resistance and regulated radiation-induced apoptosis through CD47 mediated 
signaling pathway112, 113. It also has been reported that Thbs-1 is involved in 
tumorigenesis as a tumor suppressor gene, similar to Lxn107, 114. Its expression is 
either down-regulated or absent due to hypermethylation in cancer cells. Thbs-1 
deficient mice developed tumor earlier in a p53 null background, supporting its 
role as a putative tumor suppressor gene115. Further, Thbs-1 positively regulates 
apoptosis116. It regulates radiation-induced apoptosis through CD47 signaling 
pathway112, 117.To test the hypothesis that Thbs-1 expression correlate with Lxn 
expression, we overexpressed Lxn in FDC-P1 cells. Using Q-PCR we found that 
in FDC-P1 cells overexpressing Lxn, the expression level of Thbs-1 was up-
regulated with Lxn overexpression. The studies mentioned above indicate Thbs-1 
may be a potential target of Lxn.  
In conclusion, I found that loss of Lxn induced hyperproliferative 
hematopoiesis resulting from decreased apoptosis. Loss of Lxn also confered a 
cell-autonomous repopulation advantage and elevated self-renewal capacity, 
indicating enhanced stem cell functions in Lxn-/- animals. 
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Figure 2.1 Generation of Lxn deficient ( Lxn-/-) mice. 
(A) The Lxn wild-type locus, the targeting vector, and the Lxn targeted allele with the 
Lxn constitutive knock out allele. (top to bottom). Coding regions are shown as filled 
squares labeled with exon numbers. The targeting vector introduced a functional 
excision sequence flanking exons 2 to 4 of the Lxn gene that resulted in the excision 
of exons 2-4 after in vivo Cre deletion. (B) Western blots of Lxn expression in various 
tissues of wild type B6 and Lxn-/- mice. Total protein from BM, spleen, liver and brain 
were probed with anti-Lxn or anti-Gfm-1 antibody, respectively.  
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Figure 2.2 Proliferative hematopoiesis in Lxn-/- mouse.  
(A) Enlarged spleens and expanded red pulp in Lxn-/- mice (n=11) compared with 
wild type B6 mice (n=12). (B) Flow cytometry analysis using lineage-specific markers, 
Gr-1/Mac-1 (myeloid), B220 (B cell) and Thy-1 (T cell), comparing the proportion of 
each cell types in the spleens of Lxn-/- and B6 mice (n>10 in each experiment). (C) 
Peripheral blood cells were quantified by using the Hemavet cell counter. The 
numbers of total white blood cell, lymphocyte, neutrophil, monocyte and platelet 
were compared between Lxn-/- and B6 mice (n>20 in each experiment). * indicated 
a P<0.05 hereafter.  Error bar represented standard deviation (SD) hereafter if not 
indicated. 
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Figure 2.3 Stem cell and progenitor quantification by using phenotypic 
marker and flow cytometry. 
 (A) Flow cytometric analysis of immunological cell surface makers were used in 
identifying the frequency of progenitor and stem cells. Serial gating and marker 
panels for each subpopulation (LT-HSC, ST-HSC, MPP, CLP, CMP, GMP, MEP and 
LSK) are listed above. 
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Figure 2.3 continues (B) BM cellularity (cell number/femur) in Lxn-/- mice (n=26) 
compared with wild type B6 mice (n=8). (C) Flow cytometric analysis showed an 
increased LSK population in Lxn-/- BM cells that due to an expanded MPP 
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population. (D) and (E) Flow cytometric studies revealed that LSK cells, multi-potent 
progenitors (MPPs) and lineage committed progenitors (CLPs, CMPs, and GMPs) 
were relatively increased in  Lxn-/- BM cells. In (C), (D) and (E), each experiment 
was repeated 3 times, and at least 3 animals were pooled in each group. 
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Figure 2.4 Functional analysis of Lxn-/- mice.  
(A) Day 14 colony-forming cells formed per 10
4
 cells in Lxn-/- mice (n=5) and B6 
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mice (n=4). (B) The frequency of CAFCs formed at day 35 in Lxn-/- (n=4) and B6 
(n=3) animals. Panels C, D, E and F are flow cytometric analysis of competitive 
repopulation experiments with Lxn-/- and B6 mice (n=10 in each experimental group). 
(C) Flow cytometric analysis of engraftment efficiency of donor derived cells in PB of 
recipients at 5, 10 and 15 weeks post competitive transplantation. (D) Flow 
cytometric analysis of the percentage of donor-derived cells in BM of recipients at 15 
weeks after competitive transplantation. (E) Flow cytometric analysis of the 
percentage of donor derived LSK cells in PB of recipients at 15 weeks post 
competitive transplantation. (F) Determination of the lineage distribution of myeloid, 
T and B cells in the PB of donor animals in transplanted recipients at 15 weeks post 
transplantation. Error bar represented standard error of the mean (SEM) in Fig. 2.4B. 
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Figure 2.5 Serial transplantation and reciprocal transplantation with Lxn-/- 
mice and B6 mice. 
 (A, B and C) Self-renewal analysis of HSCs using serial transplantation. Lxn-/- (two 
independent experiments; n=10) or B6 (two independent experiments; n=10) derived 
peripheral blood leukocytes (A), BM nucleated (B) and BM LSK cells (C) were 
analyzed 15 weeks post transplantation in primary, secondary and tertiary recipients. 
(D and E) 5x10
6 
unfractionated BM cells were transplanted into either B6 (n=5) or 
Lxn-/- recipients (n=5). (D) Donor-derived PB leukocytes were analyzed At the 5, 10 
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and 15 weeks post transplantation. (E) Lineage distribution of donor-derived myeloid, 
T and B cells in PB cells 15 weeks post transplantation. 
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Figure 2.6 Alteration in apoptosis in Lxn-/- hematopoiesis.  
(A) Flow cytometric analysis of BM cells stained with Annexin V (plus PI) 
distinguished cell subsets that are apoptotic (PI
-
 /Annexin V
+
) in multiple cell sub-
populations.(B) Decreased frequency of apoptotic cells in Lxn-/- mice compared to 
B6 mice in MPP, ST-HSC and LT-HSC populations. 
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Table 2.1 Genes differentially expressed in Lxn-/- MPP cells 
Gene Contrast 
HSPA1A +3.6 
RNASE3 +2.0 
TSEN15 +1.9 
GAS5 +1.9 
HSPS1 +1.8 
KIR3DL2 -1.76 
GFI1B -1.77 
SLC18A -1.83 
TRPC6 -2.3 
THBS-1 -3.49 
Microarray experiments were performed in LSK/CD34
+
/Flt-3
+ 
MPP BM cells obtained 
from B6 and Lxn-/- mice using Affymetrix Gene Chip MoGene-1_0-st-v1 arrays. 
Table 2.1shows top five of the most highly under-expressed or expressed genes with 
a significance threshold of 0.01. 
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Figure. 2.7 Thbs-1 expression level in Lxn-/- HSPCs. 
Thbs-1 expression levels along hematopoietic differentiation hierarchy were 
identified by Q-PCR.  
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Figure. 2.8 Flow cytometric analysis of lineage distribution in PB. 
Flow cytometry using lineage-specific markers, Gr-1and Mac-1 (myeloid cells), Thy-1 
(T cells), and B220 (B cells), showed an altered lineage distribution in PB in Lxn-/- 
mice (n=13) compared to B6 mice (n=8). 
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Figure 2.9 Transplantation strategy.  
(A) In competitive repopulation (CR) assays, 1x10
6 
WBM cells from Lxn-/- mice or B6 
test cells (both CD45.2) were mixed with an equal number of competitor cells 
A 
B 
C 
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(CD45.1), and retro-obitally injected into lethally irradiated (9 Gy) CD45.1 recipient 
mice (B6.SJL/BoyJ). (B) In serial transplantation, one million test cells (CD45.2 
isotype) are mixed with an equal number of competitor cells (CD45.1 isotype) and 
are transplanted to lethally irradiated primary recipients. At 15 or 16 weeks post 
transplantation, 10x10
6 
unfractionated bone marrow cells were harvested from 
primary recipients and transplanted cells into lethally irradiated secondary recipients. 
The same regimen was repeated for tertiary transplantation. (C) In reciprocal 
transplantation, 5x10
6 
unfractionated bone marrow cells (CD45.1) were transplanted 
into either B6 or Lxn-/- recipients (both CD45.2).  Engraftment efficiency was 
measured at 5, 10 and 15 weeks transplantation. 
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Figure 2.10 Lacking of alteration in cell cycle status and proliferation in 
Lxn-/- HSPCs.  
(A) a representative scatter plot for Ki67 cell cycle analysis. Flow cytometric analysis 
of BM cells stained with Ki-67 (combined with DNA dye 7-AAD) distinguishes cell 
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subsets that in G0 (Ki-67
- 
7-AAD
-
), G1 (Ki-67
+
 7-AAD
-
), and S/G2/M (Ki-67
+
 7-AAD
+
) 
phase. (B) Cell cycle status in Lxn-/- and B6 MPP populations. (C) Proliferative 
profile of HSPC subsets. Mice were exposed to BrdU for three days prior to analysis. 
MPPs, ST-HSCs and LT-HSCs were analyzed for BrdU incorporation (BrdU
+
).  
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CHAPTER 3: Loss of Latexin in Murine Hematopoietic Stem and Progenitor 
Cells Mitigates Ionizing Radiation Toxicity 
3.1 Abstract 
Bone marrow injury is one of the major adverse side effects of radiation 
and chemotherapy; however, treatments that can mitigate such injury are very 
limited.  To manage radiation or chemotherapy induced bone marrow injury, we 
need a better understanding of how radiation harms bone marrow cells and their 
environment, as well as how bone marrow cells react to such stress. In this study, 
we discovered a role for Latexin (Lxn) in the radio-sensitivity of hematopoietic 
stem and progenitor cells. We found that loss of Lxn in mice confers resistance to 
lethal and sub-lethal radiation. Lxn deletion protected 3 out 5 mice (60%) from 8 
Gy irradiation, while no mouse survived in the wild type group. After exposure to 
sub-lethal irradiation, the LSK cell population expanded ~5-fold two weeks post 
irradiation in Lxn-/- animals, suggesting a rapid recovery to radio-resistance at 
the HSC/HPC level. Further, Lxn-/- mice displayed an enhanced hematologic and 
immune recovery 3 - 14 days after irradiation, with elevated numbers of total 
leukocytes, lymphocytes, granulocytes and platelets. We then studied the 
underlying mechanism that accelerates regeneration of hematopoiesis in bone 
marrow after irradiation, and found that ablation of Lxn suppressed apoptosis in 
primitive progenitor cells (LSK). In conclusion, our data indicate that Lxn 
promotes irradiation-induced apoptosis and loss of Lxn conferred a radiation 
resistance through regulating hematopoietic recovery. These findings provide a 
novel potential therapeutic target for protecting HSPCs in patients undergoing 
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radiotherapy or exposed to environmental radiation. 
3.2 Introduction 
Maintaining a stable supply of mature blood cells is essential for nutrient 
supply, pathogen defense, and tumor surveillance in hematopoiesis. However, 
this homeostasis can be perturbed by DNA-damaging agents such as ionizing 
radiation. Ionizing radiation is high-frequency radiation that has the capacity to 
remove an electron from an atom. When ionizing radiation pass through a cell, its 
high energy causes intracellular atoms and molecules to become excited, or 
“ionized”. This ionization can break chemical bonds, produce free radicals, and 
damage molecules45. At low doses of ionizing radiation, hematopoietic cells 
trigger a rapid recovery response and amend certain levels of damage46, 47. 
However, DNA mutation may still occur that could lead to tumorigenesis in the 
future. When exposed to high doses of ionizing radiation, hematopoietic cells fail 
to repair themselves and undergo programmed cell death (apoptosis) 45, 48. 
Therefore, ionizing radiation induced-apoptosis is necessary to balance 
tumorigenesis prevention and organismal survival. We propose that low levels of 
apoptotic activity are beneficial to tissue regeneration and may promote the 
restoration of hematopoiesis when cells are exposed to high doses of ionizing 
radiation.  
We previously discovered a role for Lxn in inhibiting tumor growth through 
promoting apoptosis in cancer cells107 (Chapter 5). Ectopic overexpression of Lxn 
in murine lymphoma cells (A20 cell line) slowed their growth rate in vitro and 
inhibited tumor formation in vivo by significantly increasing apoptosis through the 
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down-regulation of two anti-apoptotic genes: Bcl-2 and Pim-2107. Furthermore, in 
mice lacking Lxn expression (Lxn-/-) we observed expanded hematopoiesis due 
to decreased apoptosis activity in progenitor and stem cells (Chapter 2). These 
phenomena are consistent with what we previously observed in a study with 
congenic animals in which Lxn expression was positively correlated with 
apoptotic frequency in hematopoietic cells93. These findings implicate Lxn as a 
pro-apoptotic factor, and prompted us to explore Lxn function under genotoxic 
stress, such as radiation, where apoptosis is critical to tissue regeneration.  
In the present study, we demonstrated that deletion of Lxn allows mice to 
withstand lethal and sub-lethal doses of radiation. Remarkably, loss of Lxn 
protected hematopoietic progenitor and stem cells from ionizing radiation, and 
accelerated both hematopoietic and immunologic recovery. Further, Lxn 
deficiency significantly suppressed radiation-induced apoptosis in hematopoietic 
progenitor and stem cells. In conclusion, our findings provide evidence that 
deletion of Lxn may be a novel strategy for promoting HSPC recovery in patients 
undergoing radiotherapy or following accidental radiation.  
3.3 Methods 
3.3.1 Animals 
Young C57BL/6 (B6) mice (8-16 weeks) were purchased from The 
Jackson Laboratories (Bar Harbor, ME).  Latexin constitutive knockout mice were 
generated by Taconic/Artemis (Germantown, NY) and used at a young age (8-16 
weeks). Male animals were used in this study. All animals were housed in the 
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animal facilities of the University of Kentucky under pathogen-free conditions 
according to NIH-mandated guidelines for animal welfare and were given food 
and water ad libitum. 
3.3.2 Ionizing radiation 
The mice and cells were exposed to various doses of radiation (6.5 Gy, 8 
Gy, 9 Gy and split doses of 12 Gy) in a 137 Cs gamma irradiatior (J.L. Shepherd 
and Associates, Glendale, GA) at a dose rate of 153 rad/min. 
3.3.3 Peripheral blood cell counts. 
Animals were anesthetized with isoflurane (Butler Animal Health Supply, 
Dublin, OH).  Peripheral blood was collected from retro-orbital venous plexus into 
EDTA-coated microtainer tubes (Becton, Dickinson and Company, Franklin lakes, 
NJ).  Circulating leukocytes, erythrocytes and platelets were counted by 
analyzing 20 ul of blood using a Hemavet 950 (Drew Scientific, Dallas, TX). 
3.3.4 Hematopoietic cell identification and isolation 
Bone marrow cells were flushed from the femora and tibiae using a 1 ml 
syringe and 22G needle into Hanks balanced salt solution (HBSS) with 2% fetal 
bovine serum (FBS) (Gibco, Grand Island, NY). Progenitor cells were 
discriminated from stem cells by the lack of cell surface antigens characteristic of 
cells committed to individual lineages.  Antibodies against these antigens 
included CD5 and CD8a, B220, Mac-1, Gr-1, and Ter119 were biotinylated. 
Strepavidin secondary antibody was used to detect lineage negative cells. To 
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further purify primitive stem cells, the stem cell markers Sca-1 and c-Kit were 
incorporated into the staining procedure.  Dead cells were excluded by propidium 
iodide (PI) that stains exposed double-strand DNA.  All monoclonal antibodies 
were purchased from eBioscience (San Diego, CA), Biolegend (San Diego, CA), 
or BD Pharmingen (San Jose, CA). 
3.3.5 Cell analysis and sorting 
Bone marrow cells were analyzed and sorted on a BD FacsAria II flow 
cytometer (Becton Dickinson, Franklin Lakes, NJ). Cells were sorted into 
phosphate buffered saline (PBS) with 0.5% FBS for further use. Flow cytometry 
data was analyzed using FlowJo software (Tree star, Ashland, OR). 
3.3.6 Apoptosis analysis 
Bone marrow cells were prepared and stained as described above. The 
fluorochrome-conjugated apoptotic marker Annexin V along with Propidium 
Iodide (PI) (both from BD Pharmingen) were used to identify apoptotic cells (PI-
/Annexin V+). Stained cells from Lxn-/- animals and B6 animals were analyzed by 
flow cytometer. 
3.3.7 Colony forming cell (CFC) assay 
Methylcellulose-based culture media (MethoCult) was purchased from 
Stem Cell Technologies, Vancouver, Canada and contained the following 
cytokines: stem cell factor (SCF), IL-3 and IL-6.  For this assay, 5 x 104 whole BM 
cells in 100 µL HBSS were thoroughly admixed with 1 mL complete MethoCult 
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media, plated into petri-dishes, and incubated at 37°C. Individual wells of 
duplicates were counted on day 10 to quantify lineage specific colonies. 
3.3.9 Statistics 
Statistical significance between means was determined by a two-way 
Student t test.   
3.4 Results 
3.4.1 Loss of Lxn mitigates lethal and sub-lethal irradiation with various doses 
From previous studies, a pro-apoptotic role of Lxn has been observed93, 
107. In order to further study Lxn function in response to hematopoietic stress 
induced-apoptosis, we used Lxn constitutive knock-out mice as a model and 
treated the mice with ionizing radiation. The Lxn deficient mouse model was 
generated by Taconic/armetis with a deletion of exons 2-4 in the Lxn gene which 
results in the disruption of the protein (Chapter 2). We first studied the effects of 
loss of Lxn in BM cell radiation resistance. Total body irradiation (TBI) was 
administrated to both Lxn-/- mice and B6 control mice. We tested various 
dosages of gamma radiation including lethal doses of 8 Gy and 9 Gy, as well as 
clinically relevant split doses totaling 12 Gy. We then studied the survival rate for 
each treatment. As expected, all of the lethally irradiated B6 animals died within 
20 days after receiving a single 8 or 9 Gy dose (Fig. 3.1A). Surprisingly, the 
survival rate of Lxn-/- mice was significantly greater. As shown in Fig 3.1A, 60% 
of the Lxn-/- mice survived the 8 Gy dose of irradiation and 20% of Lxn-/- mice 
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survived the 9 Gy dose. To further characterize the radio-protective effect and 
study its implication in medical treatment, we irradiated two experimental groups 
with 12 Gy TBI using a fractionated schedule of 2 Gy every 12 hours. Consistent 
with our previous results, all of the knockout animals survived, whereas only 4 
out of 5 wild type mice survived (Fig. 3.1B).  
3.4.2 Loss of Lxn promotes the recovery of hematopoietic stem/ progenitor 
cells post radiation exposure 
HSCs and HPCs are vital to long-term and short-term recovery after 
ionizing radiation. To elucidate the underlying mechanism of radio-resistance in 
Lxn-/- mice, we studied the recovery of HSCs and HPCs after radiation exposure.  
A single dose of 6.5 Gy TBI (sub-lethal dose) was administrated to both 
experimental groups (Lxn-/- mice and wild-type B6 mice). The recovery of HSPC 
post irradiation was determined by both flow cytometer (which counts phenotypic 
HSPC) and in vitro colony-forming unit (CFU) assay (which measures functional 
HSPC) in a time dependent manner. At each time point, we harvested BM cells, 
analyzed BM cellularity, and measured the size of the surviving LSK cell 
population in both groups. The number of phenotypic HSPCs (LSK cells) in Lxn-/- 
mice was significant greater than B6 mice before irradiation and 3 days after 
exposure to irradiation (Fig 3.2A). LSK cell counts dropped dramatically at day 7 
in both experiment groups. However, the HSC recovery rate was accelerated in 
Lxn-/- mice. The number of LSK cells compartment increased approximately 6-
fold at day 14 and 3-fold at day 21 in Lxn-/- mice (Fig 3.2A and B). The numbers 
of LK (Lin-/c-Kit+/Sca-1-) and LS (Lin-/c-Kit-/Sca-1+) cells were also increased at 
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day 14, though not to the same extent of LSK cells. These data indicate that 
deletion of Lxn selectively protects primitive cells more so than differentiated cells 
(Fig 3.2B).  
In flow cytometric analysis, we used phenotypic markers to quantify HSPC 
numbers. To further identify the numbers of functional HSPCs, we performed 
CFU assays with 5x104 whole BM cells from 6.5 Gy sub-lethally irradiated 
animals. The pattern of HSPC recovery in Lxn-/- mice is similar to what we 
observed using phenotypic markers. Lxn-/- whole BM cells from mice at day 0, 1, 
3,14 and 28 post irradiation formed significantly more colonies, which indicated 
an accelerated recovery rate compared to B6 cells (Fig. 3.2C). This observation 
supported previous LSK cell population frequency results.  
We also observed a similar trend in BM cell recovery. The numbers of 
surviving whole BM cells were significantly diminished (24~28 million cells per 
femur to less than 3 million cells per femur) shortly after irradiation (day 3), and 
subsequently stable returned back to normal levels by day 28 in Lxn-/- mice (Fig. 
3.2D). Lxn-/- BM cells showed an accelerated recovery rate over B6 BM cells at 
day 7, 14 and 28 (Fig. 3.2D), in accordance with increased tempo in recovery of 
HSPCs (Fig. 3.2A). Collectively, our results showed that deletion of Lxn up-
regulates radio-resistance by promoting HSPC recovery and speeding the 
regeneration of BM hematopoiesis after irradiation. 
3.4.3 Loss of Lxn facilitates hematologic and immunologic recovery post 
radiation exposure 
Radiation-induced hematological failure and immune failure are the 
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primary causes of low survival after high dose radiation exposure. To further 
address the question of how Lxn deletion results in radiation resistance, we 
examined the hematologic and immune recovery in a time dependent manner 
following radiation exposure. Wild type B6 and Lxn-/- animals were exposed to a 
sub-lethal (6.5 Gy) dose of radiation to trigger reversible hematopoietic injury. We 
then monitored the rate of recovery of blood cells. As demonstrated in Fig. 3.3A, 
loss of Lxn significantly accelerated the recovery of total leukocytes in blood. 
Untreated Lxn-/- mice have ~ 30% more leukocytes than their wild type 
counterparts (Fig. 3.3A). Leukocytes in both strains dropped to approximately 
1,000 cells/ul in peripheral blood one day after irradiation. The number of Lxn-/- 
leukocytes rapidly recovered at day 7 and remained significantly greater than B6 
(approximately 100% more) up to day 14. The counts of neutrophils (Fig. 3.3B) 
and lymphocytes (Fig. 3.3B and C) had similar recovery patterns as the total 
leukocytes. Lxn-/- mice showed a faster recovery over the period from day 7 to 
28 compared to B6 animals. The level of neutrophil counts in both groups 
overshot normal levels, whereas lymphocytes never fully recovered. Platelet (Fig. 
3.3D) counts in both groups recovered to normal by day 28. The number of Lxn-/- 
platelets was significantly greater than B6 platelets 3 ~ 7 after irradiation. 
Collectively, a recovery advantage was observed at multiple time points in both 
hematologic and immune systems in PB, possibly resulting from accelerated 
recovery in HSPCs in BM. 
We also studied the lineage distribution of mature blood cells between 
granulocyte, monocyte, T-cell and B-cell lymphocytes using various lineage 
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markers. The gamma irradiation caused immediate lympho- and myelo-ablation 
at day 1 and an altered lineage distribution that favored the myeloid lineage (Fig. 
3.3E). The lymphoid lineage started to gradually recover 3 days after radiation. 
The distribution of B lymphocytes in Lxn-/- mice recovered to near normal (50%), 
but B6 B lymphocytes never fully recovered (30%) (Fig. 3.3E). This result is 
consistent with what we observed in animals transplanted with Lxn-/- BM cells. 
Lxn-/- cells showed a preference for B-cell production in reconstituted 
hematopoiesis. In sum, our results indicate that the recoveries of total leukocyte, 
platelet, granulocyte and lymphocyte subsets were accelerated in Lxn-/- mice 
following ionizing radiation. Further, Lxn-/- cells favor B cell lineage production in 
long-term reconstitution. 
3.4.5 Lxn ablation diminished radiation-induced apoptosis in hematopoietic 
stem/ progenitor cells 
We previously reported that Lxn regulates cell populations through its role 
in apoptosis. Here we hypothesized that loss of Lxn renders HSCs and HPCs 
more resistant to apoptosis after exposure to ionizing irradiation. To test this 
theory, we directly examined the apoptotic frequency using Annexin V staining, 
and found the percentage of apoptotic LSK cells was significantly lower in Lxn-/- 
mice after 6.5 Gy sub-lethal irradiation (Fig. 3.4A). During homeostasis, apoptotic 
cell frequency is inherently significantly lower in Lxn-/- LSK cells (day 0 in Fig. 
3.4A). This low apoptotic frequency was sustained from day 7 to day 28 after 
irradiation. On day 14 the percentage of apoptotic LSK cells was 5-fold lower in 
Lxn-/- mice compared to B6 mice (Fig. 3.4A, B and C). Notably, the percentage of 
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apoptotic cells in Lin-, LK and LS subpopulations diminished along with Lxn 
ablation on day 14, but did not reach statistical significance (Fig. 3.4C). The 
apoptotic frequency was significantly reduced only in LSK cells, indicating that 
loss of Lxn selectively affected the apoptotic rate in primitive BM cells.  
3.5 Discussion 
Exposure to moderate or high doses of total body irradiation leads to long-
term irreversible hematopoietic injury. This injury has been attributed to 
quantitative and qualitative damages to hematopoietic cells. Radiation-induced 
apoptosis and senescence are the major cellular mechanisms which induce 
quantitative or qualitative radiation-induced damage to stem cells, respectively48, 
50. From previous studies we learned that a majority of HSCs die after radiation 
exposure by triggering apoptosis49, 118. The apoptotic activity of the cells is critical 
for regulating the radiation-resistance and survival rate after exposure to high 
doses of radiation.  
In vivo proapoptotic functions of Lxn were previously demonstrated in B 
lymphoma cells107. Furthermore, in mice lacking Lxn expression (Lxn-/-) we 
observed expanded hematopoiesis due to decreased apoptotic activity in 
progenitor and short-term HSCs (Chapter 2). These results suggest that Lxn 
regulates apoptotic activities of hematopoietic cells. In this chapter, we studied 
the function of Lxn in response to ionizing radiation, under which apoptotic 
activities are key factors in post radiation recovery, using Lxn deficient mouse as 
a model. 
We first examined the radio-protective activities of Lxn in murine 
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hematopoiesis by studying the survival rates of Lxn-/- and B6 mice after lethal 
doses of radiation exposure. When exposed to lethal doses of total body 
irradiation (above 7.5 Gy, single dose), death is usually caused by hematological 
failure119-121. Three days after radiation, BM cell counts (both leukocytes and 
platelets) drop dramatically. Another target organ of irradiation-induced injury 
potentially leading to mortality is the small intestine122. However, previous reports 
demonstrated a rapid recovery of the small intestine injured at the level when 
exposed to 7.5~9 Gy, suggesting that gut injury is not the primary cause of death 
at these doses of radiation. In this study, we performed 8, 9, and 12 Gy split 
doses of radiation to study Lxn function on the survival rate of Lxn-/- mice. 
Administrating 12 Gy TBI using a fractionated schedule of 2 Gy every 12 hours is 
a clinically relevant and is roughly equal to a single dose of 7 Gy irradiation123. 
We employed this radiation dose in order to demonstrate the potential radio-
protective function of Lxn deficiency which may benefit patients undergoing 
radiotherapy. The results showed that loss of Lxn leads to the long-term survival 
of more than 60% of the Lxn-/- mice irradiated with 8 Gy, whereas all wild type B6 
mice succumbed. However, Lxn-/- mice showed only a 20% increases in the 
survival rate after 9 Gy as well as split doses of 12 Gy radiation. These results 
suggested that the effective window of Lxn deficiency is quite limited and its 
effect in mitigating radiation-induced mortalities is dose-dependent. 
When given a sub-lethal dose of radiation, leukocyte and platelet counts 
drop off shortly after radiation exposure. However, unlike after a lethal dose of 
irradiation, HSPCs that survive a sub-lethal dose reconstitute hematopoiesis 
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within 8 weeks after radiation exposure50. To further characterize the function of 
Lxn in mitigating radiation-induced BM failure, mice were exposed to a 6.5 Gy 
sub-lethal dose of total body irradiation. The hematopoietic recovery was closely 
monitored and our results show that the loss of Lxn significantly accelerates the 
recovery of both leukocytes and platelets. Measurements of CFCs in the BM at 
day 10 post radiation conclusively demonstrate the hematopoietic progenitor cell 
numbers are increased in Lxn-/- mice. Increased frequencies of BM LSK cells 
(stem cells) and LK cells (progenitor cells) indicate that loss of Lxn promotes the 
recovery of hematopoiesis at the level of stem cell/progenitor cells. Lxn-/- mice 
exhibit an endogenous, proliferative hematopoiesis, including higher levels of 
leukocytes, increased BM cellularity, and increased HSC numbers (LSK cells) 
under homeostasis (which continuously stay higher during hematologic recovery). 
However, this advantage diminishes after hematopoiesis is reconstituted. A 
possible explanation for this observation is replicative exhaustion in which stem 
cells lose their functional capacity after periods of active proliferation and 
differentiation.    
How does the loss of Lxn facilitate hematopoietic stem/progenitor recovery 
post irradiation? Ionizing radiation produces free radicals that damage DNA 
content and induces apoptotic and mitotic death49. As we hypothesized, Lxn 
deficiency may protect HSPCs from apoptosis. Our data shown in Fig.3.4 
indicates that loss of Lxn decreases apoptosis in irradiated hematopoietic stem 
and progenitor cells, especially stem cells (LSK cells). Another possibility that 
could induce a rapid recovery after radiation is an advantage in cell proliferation. 
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Increased cell proliferation activity will expand the cell population and accelerate 
hematologic recovery. In previous studies, we found that the loss of Lxn does not 
affect proliferation and cell cycling activities in stem and progenitor cells under 
homeostasis. Therefore, in this paper, we did not examine the proliferative 
activities during hematologic recovery. However, it is possible that the loss of Lxn 
may influence cell cycling status and proliferation after radiation exposure. In the 
future we will test the proliferative activities of HSPCs after sub-lethal doses 
radiation using BrdU incorporation, which labels newly synthesized DNA in 
proliferating cells.  
From studies on B lymphoma cells, we found that Lxn overexpression 
decreased the expression of the anti-apoptotic gene Bcl-2 and inhibited tumor 
cell growth through promoting apoptosis107. Apoptosis is controlled by a balance 
of positive (pro-apoptotic) and negative (anti-apoptotic) signals. Decreased levels 
of Bcl-2 allow other pro-apoptotic proteins to aggregate and induce apoptosis 124.  
Tumor suppressor p53 is a regulator of Bcl-2125, 126. Induction of p53 resulted in a 
decreased expression level of Bcl-2125. The p53 signaling pathway is central in 
ionizing radiation-induced apoptosis127-129. It is possible that the mechanisms 
underlying Lxn -/-induced radio-resistance are involved in p53 and Bcl-2 
mediated apoptosis pathways. In future studies, we will test the expression level 
of the key players in p53 mediated signaling pathway such as MDM2/X, 
phospho-p53, p53, Bcl-2, Bax and Bad using immuno-blots. 
Another potential candidate gene involved in Lxn induced-apoptosis is 
Thbs-1. We have demonstrated a significantly decreased level of Thbs-1 in Lxn-/- 
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multipotent progenitor cell population, compared to wild-type animals. Thbs-1 null 
mice showed a radio-resistance130, similar to what we observed in Lxn-/- mice.  It 
has been reported that Thbs-1 is involved in regulating radiation-induced 
apoptosis through CD47-mediated signaling pathway112, 117. In future experiments, 
we will study Thbs-1 as a potential target gene of Lxn by overexpressing Thbs-1 
in Lxn-/- BM cells and transplant the transduced cells. Radio sensitivities will be 
tested in recipients transplanted with transduced or control Lxn-/- cells. 
Premature senescence and tumorigenesis are two possible outcomes of 
radiation exposure other than apoptosis. It was previously reported that a small 
portion of surviving HSCs lose their expansion and self-renewal capacities after 
radiation exposure50. In Fig. 3.2 A and B, we showed that HSC numbers (LSK 
cells) in Lxn-/- mice were significantly increased compared to B6 mice. But do 
these phenotypically defined HSCs function normally? To explore the answer to 
this question, CAFC assays or in vivo transplantation assays will be used to 
measure the functional activities of HSCs. Also, a small number of cells survive 
radiation stress with chromosome aberrations which can result in tumorigenesis. 
To address this scenario, we monitored the surviving mice after split doses of 12 
Gy radiation for 8 months. Their hematologic and immune parameters remained 
within the normal range (data not shown), and no tumorigenesis occurred in 
irradiated Lxn-/- mice. These observations suggest that the loss of Lxn confers 
little genetic instability while preventing apoptosis after radiation exposure. The 
loss of Lxn is unlikely to promote cancer growth in the irradiated mice. 
In conclusion, the loss of Lxn protects HSPCs against lethal and sub-lethal 
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radiation and promotes hematopoietic and immune recovery post radiation 
exposure by regulating apoptotic activities in HSPCs. Studying the mechanisms 
underlying Lxn radio-sensitive function provides a novel potential therapeutic 
target for protecting HSPCs in patients undergoing radiotherapy and mitigating 
toxicity from environmental radiation. 
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Figure 3.1 Kaplan-Meier curves demonstrate survival rate. 
(A) Kaplan-Meier survival curves of mice exposed to lethal total body irradiation. 
B6 and Lxn-/- mice (n=5 for each experimental group) were given a single dose 
of 8 or 9 Gy irradiation, and monitored for their survival. (B) Kaplan-Meier survival 
curves of mice exposed to clinically relevant total body irradiation. Mice (n=5 for 
each experimental group) were given a total of 12 Gy (2 Gy administrated 6 
times). * indicated a P<0.05 hereafter. 
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Figure 3.2 Ablation of Lxn confers protection of HSPCs against gamma-
irradiation and speeds recovery.  
B6 and Lxn-/- mice (n=3 for each experimental group) were irradiated with a sub-
lethal 6.5 Gy dose of irradiation. We then monitored bone marrow progenitor and 
stem cell kinetics for 56 days post radiation. (A) The numbers of surviving LSK 
cell in one femur were compared between the two groups. (B) Flow cytometric 
analysis showed the expanded LSK, LK, and LS cell populations at day 14 post 
irradiation for both Lxn-/- and B6 mice. (C) The frequencies of hematopoietic 
stem and progenitor cells were determined by in vitro colony forming cell assay. 
(D) The numbers of surviving bone marrow cells in one femur were compared 
between two groups. 
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Figure 3.3 Ablation of Lxn promote hematological recovery at HSPC level. 
B6 and Lxn-/- mice (n=3 for each experimental group) were irradiated with a sub-
lethal 6.5 Gy dose and their hematologic and immunologic recovery was 
monitored in peripheral blood over 56 days. The counts of total leukocytes (A), 
neutrophils (B), lymphocytes (C) and platelets (D) were determined by using a 
Hemavet cell counter. (E) Differentiated lineage cells were measured by flow 
cytometer using lineage-specific antibodies (Gr-1, Mac-1, B220 and Thy-1). 
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Figure 3.4 Lxn ablation in mice diminished radiation-induced apoptosis in 
progenitor and stem cells.  
 B6 and Lxn-/- mice (n=3 for each experimental group) were irradiated with a 
sub-lethal 6.5 Gy dose of radiation. Apoptotic activities in HSPCs were measured 
d.p.i 
14 d.p.i 
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using the apoptotic marker Annexin V and flow cytometry. (A) The flow cytometric 
analysis of apoptotic cells on day 14 post irradiation using Annexin-V and DNA 
dye staining. (B) Analysis of apoptotic rate dynamics (over 56 days post 6.5 Gy 
irradiation) in the LSK population. (C) The apoptotic frequency of LSK, LK, LS 
and LIN- sub-populations in Lxn-/- animals in day 14 post radiation. 
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CHAPTER 4: Loss of Latexin Compromises Progenitor and Stem Cell 
Retention and Results in An Enhanced Mobilization in Murine 
Hematopoiesis  
 
4.1 Abstract 
Engraftment and maintenance of hematopoietic stem and progenitor cells 
(HSPC) depends on their interaction with a specific bone marrow (BM) 
microenvironment, commonly known as the niche.  Mobilization of HSPCs from 
niche into peripheral blood in response to granulocyte colony-stimulating factor 
(G-CSF) involves detachment of HSPCs from stromal cells, which make up a 
large portion of the niche. The influence of latexin (Lxn) on stem/progenitor cell-
stroma interactions has not yet been studied. Using G-CSF-induced mobilization 
in Lxn deficient (Lxn-/-) mice, we found that the number of phenotypically 
identified HSPC (Lin-c-Kit+ cells) mobilized into the bloodstream is about 2-fold 
greater in Lxn-/- mice.  In vitro adhesion assays showed that the adhesive 
properties of hematopoietic cells are compromised in Lxn-/- animals, perhaps 
allowing them to spill into the bloodstream more easily.  Microarray experiments 
on multipotent progenitor cells identified several pathways that were altered upon 
Lxn deletion. The signaling pathways of cell-to-cell and cell-to-ECM interaction 
were significantly reduced, implying an enhanced mobilization efficiency in 
primitive hematopoietic cells from Lxn-/- mice. These findings may explain the 
reduced adhesion of hematopoietic progenitor cells to stroma in Lxn-/- mice. 
Amongst the genes that were significantly under-expressed, thrombospondin-1 
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(thbs-1) expression level stood out as the most down-regulated in Lxn-/- 
progenitor and stem cells.  
4.2 Introduction 
Hematopoietic progenitor and stem cells (HSPCs) reside in a cavity with 
stromal cells in the bone marrow, and this area is commonly referred to as the 
HSC niche. In their niche, HSCs remain quiescent, self-regenerate, proliferate, 
differentiate and/or migrate into the peripheral blood in response to various 
extrinsic cues. The release of HSPCs from the niche into the bloodstream is 
termed " mobilization", during which, HSPCs actively move close to sinusoidal 
vessels, pass through the vascular endothelial wall, migrate into bloodstream, 
and then infiltrate other tissues (e.g. spleen), or return to the marrow20. HSPC 
mobilization is believed to be a physiological phenomenon for maintaining 
hematopoietic homeostasis21. Redundant HSPCs in the BM niche egress into the 
bloodstream in order to balance HSPC numbers in both systems. This 
phenomenon is utilized in clinical practice to obtain adequate HSPCs from a 
transplant donor; such that mobilization cytokines are used to push large 
amounts of HSPCs into the peripheral circulation for harvesting25-29.  
HSPCs are anchored in the niche through direct cell-to-cell and cell-to-
ECM interactions. The adhesive molecules, including members from the intergrin, 
cadherin and selectin families, is essential for HSPCs retention34-36. Any 
dysregulation in adhesive molecules may affect mobilization of HSPCs. 
Previous studies show that Lxn deficient mice displayed a 
hyperproliferative hematopoiesis in BM, and there are increased numbers of LSK 
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cells  in Lxn-/- PB. Two hypothesis may explain these findings: 1) The HSPC 
population expands due to increased proliferation and/or decreased apoptotic 
activity. Excessive HSPCs egress into the blood circulation to maintain the 
homeostasis. 2) A compromised HSPC retention capacity induces increased 
mobilization. Thus, weak interactions between HSPCs and stromal cells enable 
HPSCs to readily egress into the blood circulation under homeostasis, or after 
the administration of mobilization cytokines. As mentioned previously, Lxn-/-  
mice exhibit a hyperproliferative hematopoiesis in the BM, implying that the up-
regulation of LSK population in PB is induced by homeostatic machinery. 
However, these findings are not conclusive because they do not rule out the 
influence from the microenvironmental niche cells.  
To further explore the effects of Lxn on HSPC retention capacity in the BM, 
we used G-CSF induced mobilization. We found that Lxn-/-  mice show not only 
increased mobilization proficiency, but also decreased cell retention capacities of 
Lxn -/- HSPCs. Microarray experimental results indicate that the enhanced 
mobilization proficiency of Lxn-/- primitive hematopoietic cells is correlated with 
reduced adhesion of hematopoietic progenitor cells to stroma. Thbs-1 has been 
identified as a potential target of Lxn in regulating enhanced mobilization in Lxn-/- 
mice. The expression level of Thbs-1 gradually decreases along the 
hematopoietic differentiation hierarchy in parallel with Lxn expression. I am 
currently ectopically overexpressing Thbs-1 in primitive hematopoietic cells. The 
next logical step for this project is to study the mobilization proficiency and 
retention capacity of HSPCs overexpressing Thbs-1 both in vivo and in vitro.  
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4.3 Methods 
4.3.1 Animals 
C57BL/6 mice (B6) (8-16 weeks) were purchased from The Jackson 
Laboratory (Bar Harbor, ME). Lxn constitutive knockout mice were generated by 
Taconic/Artemis (Germantown, NY) and used at a young age (8-16 weeks). All 
animals were housed in the animal facilities of the University of Kentucky under 
pathogen-free conditions according to NIH-mandated guidelines for animal 
welfare. They were fed with food and water ad libitum. 
4.3.2 Hematopoietic cell identification and isolation 
Bone marrow cells were flushed from the femora and tibiae using a 1 ml 
syringe and 22G needle into Hanks balanced salt solution (HBSS) with 2% fetal 
bovine serum (FBS). Progenitor cells were discriminated from stem cells by the 
lack of cell surface antigens characteristic of cells committed to individual 
lineages.  Antibodies against these antigens include CD5 and CD8a, B220, Mac-
1, Gr-1, and Ter119 are biotinylated. Strepavidin secondary antibody was used to 
detect lineage negative cells. To further purify primitive cells, the stem cell 
markers Sca-1 and c-Kit were incorporated into the staining procedure.  The 
multi-potent progenitor (MPP) cells are identified by immunophenotyping as cells 
negative for Lineage markers, but positive for Sca-1, c-Kit, Flt-3 and CD34. Dead 
cells were excluded by propidium iodide (PI) that stains exposed double-strand 
DNA.  All monoclonal antibodies were purchased from eBioscience (San Diego, 
CA), Biolegend (San Diego, CA), or DB pharmingen (San Jose, CA). 
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4.3.3 Cell analysis and sorting 
BM cells were analyzed and sorted on a FacsAria II flow cytometer 
(Becton Dickinson, Franklin Lakes, NJ). Cells were sorted into phosphate 
buffered saline (PBS) with 0.5% FBS for further use. Each experimental group 
was sorted independently. Flow cytometry and FACS data were analyzed using 
FlowJo software (Tree star, Ashland, OR). 
4.3.4 Mobilization assay 
To mobilize HSPCs to blood circulation, recombinant human G-CSF 
(rhuG-CSF) (Amgen Biologicals, Thousand Oaks, CA) was intra-peritoneally (i. p.) 
injected at 100 ug/kg daily for 5 days at a concentration of 12.5 ug/mL in PBS/0.1% 
BSA. HSPC frequency in PB, BM and spleen was measured by CFC assay and 
flow cytometry.  
4.3.5 Colony forming cell (CFC) assay 
Methylcellulose-based culture media was obtained with Complete 
MethoCult Media (Stem Cell Technologies, Vancouver, Canada) containing 
cytokines including stem cell factor (SCF), IL-3 and IL-6 cytokines.  For this assay, 
10 ul PB or 1 x 105 spleen cells in 100 µL HBSS were thoroughly admixed with 1 
mL complete MethoCult media, plated into 6-well petri-dish and incubated at 
37°C. Wells of triplicate cultures were counted on day 7 for PB and on day 8 or 
14 for spleen to quantify lineage-specific colonies. 
90 
4.3.6 HPC adhesion assay 
As in the CAFC assay, FBMD-1 stromal cells were pre-seeded in 96-well 
tissue culture-treated plates. After FBMD-1 cell monolayers reached confluence 
(7-10 days post plating), whole BM cells were plated at doses of 400, 800, 1600, 
3200, 6400, 12800, 25600 and 51200 per well with CAFC medium. To assess the 
progenitor cell adhesion, 2 hours later non-adherent cells were washed by gently 
aspirating the medium up and down with a micropipet, and the cells were then 
removed. Fresh medium was then added to each well. The frequency of total 
HPCs and adherent HPCs was assessed by the appearance of cobblestone-
areas in each well on day 7. The difference between the number of the 
cobblestones formed in unmanipulated wells and washed wells provided an 
index of the strength of adhesion between the CAFCs and the FBMD-1 stromal 
cells. The adhesion of HPCs was calculated by normalizing the numbers of 
cobblestones formed in washed wells to the unmanipulated wells (%). 
4.3.6 Microarray analysis 
As described in Chapter 2, microarray experiments were performed on 
fresh BM multipotent progenitor cells obtained from three wild type and three 
Lxn-/- biological samples using Affymetrix Gene Chip MoGene-1_0-st-v1 arrays. 
Data were normalized based on the RMA method131. To study pathway changes 
in response to the genomic alteration, in this chapter we performed the gene set 
enrichment analysis (GSEA) based on the GSEA Java desktop software 
application, using the same microarray experiment data132. Genes were pre-
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ranked based on the absolute values of the test statistics calculated using the 
LIMMA package in R/Bioconductor. We investigated all the pathways in the 
KEGG database. Five enriched pathways were identified with false discovery 
rate of less than 25%. Individual genes that were differentially expressed were 
identified with a p-value less than 0.01.  
4.3.7 Statistics 
Statistical significance between means was determined by a two-way 
Student t test.  
4.4 Results 
4.4.1 Mobilization of HSPCs is increased in Lxn-/- mice 
Granulocyte colony-stimulating factor (G-CSF) is widely used in clinical 
practice to stimulate the movement of stem and progenitor cells from the BM into 
peripheral blood circulation. In this study, we used G-CSF induced mobilization to 
explore the effect of Lxn in hematopoietic cell function.  Lxn-/- mice and B6 mice 
were given G-CSF daily for 5 days. Flow cytometric analysis combined with cell 
surface marker antibodies were used to identify phenotypic HSPCs in PB after G-
CSF administration. HPCs were identified by immunophenotyping as cells 
negative for lineage markers and Sca-1 antigen, and positive for c-Kit receptors 
(Lin-Sca-1-c-Kit+), whereas HSCs were negative for lineage markers and positive 
for Sca-1 and c-Kit receptors (Lin-Sca-1+c-Kit+) (Fig. 4.1A). HSPCs were negative 
for lineage markers and positive c-Kit receptors (Lin-c-Kit+) (Fig. 4.1A). Using 
92 
these parameters, we demonstrated that the mobilization of HSPCs in Lxn-/- 
mice was significantly increased (2-fold) after G-CSF administration (Fig. 4.1A 
and B). Within the HSPC population, the number of HPCs in PB was increased 
3.5-fold, whereas the number of HSCs in PB remained intact (Fig. 4.1A and B). 
These data showed that the mobilization of HPC from BM into PB was increased 
by loss of Lxn expression in hematopoietic cells. 
Colony forming cell (CFC) assay is an in vitro assay specifically measuring 
the number of functional hematopoietic progenitor cells. Next we used CFC 
assays to determine the HPC mobilization in both Lxn-/- and B6 animals. Blood 
was collected and analyzed on day 6 and the frequency of HPCs in PB was 
measured by the CFC assay. Before mobilization, PB CFC frequency in Lxn-/- 
mice is 30% more than the frequency in wild type B6 mice (Fig. 4.2A). G-CSF 
mobilized 15 and 13-fold more HPCs to PB in Lxn-/- and B6 mice respectively, 
compared to unmobilized cells (Fig. 4.2A). After mobilization, the frequency of 
CFC in the PB of Lxn-/- mice showed an increased trend compared to the 
frequency of CFCs in the PB of B6 mice, however, it did not reach the statistical 
difference (Fig. 4.2A).  
G-CSF administration not only leads to the redistribution of primitive 
hematopoietic cells from the BM to peripheral blood, but also induces their 
mobilization to spleen. Thus, we studied the frequency of CFCs in the spleens of 
Lxn-/- and B6 mice before and after G-CSF administration. Before mobilization, 
Lxn-/- mice showed a 3-fold increase in CFC frequency in spleen compared to 
wild type B6 mice (Fig. 4.2B). Post mobilization, Lxn-/- spleen CFC frequency 
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was increased 10-fold over pre-mobilization frequency, whereas B6 mobilization 
frequency was increased 25-fold (Fig. 4.2B). Mobilized Lxn-/- mice also showed 
an increased trend in CFC frequency in spleen, but which was not significant, 
compared to mobilized B6 animals (Fig. 4.2B). 
In this set of experiments, we found more HPCs (measured by CFC) in 
Lxn-/- spleen and PB compared to B6 in untreated animals (Fig. 4.2A and B). 
These data indicate that loss of Lxn could enhance the mobilization to PB and 
spleen in HPCs under homeostatic conditions. However, the frequencies of CFC 
in the PB and spleen of Lxn-/- mice showed increased trends but with no 
significant difference when compared to B6 mice. These findings were 
inconsistent with increased phenotypic HSPCs in Lxn-/- mice identified by flow 
cytometry (Fig. 4.1A and B). This may due to the sample pool size used in these 
experiments. In the future, we will repeat the CFC assays with more Lxn-/- and 
B6 animals to elucidate the functional progenitor cell numbers in PB and spleen. 
4.4.2 Loss of Lxn impaired HSPCs adhesion to stromal cells 
We next studied the adhesive properties of Lxn-/- HSPCs by directly 
measuring the adhesion of HSPCs to a bone marrow-derived stromal cells 
(FBMD-1) using the adhesion assay-a modified cobblestone-area forming cell 
(CAFC) assay. The CAFC assay is a well-established in vitro assay to measure 
HSPC activity. In this assay, stromal cells (FBMD-1 cells) were plated in a 94-well 
plate and allowed to grow to confluency. BM cells were plated in each well in 
limiting dilutions, and later scored for the presence of cobblestone-areas. Unlike 
in a traditional CAFC assay, non-adherent HSPCs were washed off 2 hours post 
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plating onto the stromal cell (Fig. 4.3A). The frequency of adhesive HSPCs was 
subsequently determined at day 7 and normalized to the frequency of HSPC in 
unwashed plates. This experiment allowed us to study the ability of HSPCs to 
anchor and adhere to the stroma in vitro. We performed the adhesion assay with 
Lxn-/- and B6 BM cells, and found that Lxn-/- BM cells showed a 40% reduction 
in the ability to adhere to stromal cells when compared to B6 compared to B6 
cells (Fig. 4.3B). This result suggests that increased mobilization of HSPC may 
be caused by compromised adhesive properties of BM cells in the niche.  
4.4.3 Decreased levels of adhesive molecules in Lxn-/- mice  
The adhesion and detachment of HSPCs from the stroma were tightly 
regulated by adhesion molecule activities. To study whether changes in 
adhesion/mobilization efficiency correlate with changes in adhesive molecule 
expression, we conducted microarray experiments on MPP cells obtained from 
Lxn-/- mice and B6 (see in Chapter 2).  Gene set enrichment analysis (GSEA) 
identified five enriched pathways that were significantly dysregulated (Tab. 4.1). 
Among these five pathways, cell-to-cell communication and ECM-receptor 
interaction pathways are involved in regulating HSPC adhesion/mobilization. The 
expression levels of most adhesive molecules were down-regulated, indicating 
that the enhanced mobilization efficiency of hematopoietic cells from Lxn-/- mice 
may be caused by reduced adhesion properties of hematopoietic progenitor cells 
to stroma (Tab. 4.2 and 3). In previous studies, the Thbs-1 gene was identified as 
one of the most down-regulated adhesion-related molecules in our microarray 
studies. Its expression level was decreased 4-fold in Lxn-/- hematopoietic multi-
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potent progenitor populations (not shown). In previous studies, we tested Thbs-1 
expression at the levels of transcript (quantitative real-time PCR) in 
hematopoietic cells and found the thbs-1 expression gradually decreased along 
the hematopoietic differentiation hierarchy, in parallel with Lxn expression (as in 
Chapter 2). To further study the in vivo role of Thbs-1 in regulating increased 
mobilization in Lxn-/- mice, Thbs-1 will be overepxressed in primitive 
hematopoietic cells and the retention properties of cells overexpressing Thbs-1 
will be tested 
4.5 Discussion 
HSCs change locations several times during embryonic development, 
shifting from the yolk sac and Aorta-gonad-mesonephros (AGM) region to the 
fetal liver, and finally to the BM19. In adult life, HSCs remain dynamic, trafficking 
between BM niches and extramedullary sites such as spleen, liver and blood in 
response to various stresses20. The periodic and diurnal release of HSCs into 
blood stream is an essential mechanism for regulating homeostasis, and 
extramedullary hematopoiesis commonly occurs in hematopoietic disorders21.  
While studying the hematopoietic system in Lxn-/- mice, we identified an 
increased HSC population in the peripheral blood system. There are two possible 
explanations for this observation: hyperproliferative hematopoiesis or 
compromised HSC retention in the BM niche. We observed hyperproliferative 
hematopoiesis in both the PB and BM of Lxn-/- mice. However, to our knowledge, 
no studies have been performed focusing on HSC retention capacity and 
mobilization in Lxn-/- mice. Here we identified a role for Lxn in regulating the 
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mobilization of HSPCs, as shown by the fact that loss of Lxn enhanced 
mobilization proficiency and decreased cell retention during homeostasis and 
after G-CSF administration. We identified that the mobilization of HSPCs 
(phenotypically identified) from BM to PB in Lxn-/- mice was significantly 
increased (2-fold) compared to B6 mice after G-CSF administration (Fig. 4.1A 
and B). However, the results from PB CFC assay found no significant difference 
between the number of CFCs formed by PB from Lxn-/- and B6 mice after G-
CSF administration. This observation may be explained by the sample size. We 
performed CFC experiments once with 3 biological samples in each experimental 
group, which may not be adequate to show statistic difference. The person who 
will carry this project will need to repeat this experiment two more time and with 
more Lxn-/- and B6 animals. The other possible explanation for this observation 
is that the progenitor mobilized into PB become non-functional, therefore would 
not form colonies. To test the hypothesis that HSPCs lose their function in Lxn-/- 
mice after mobilization, we can perform the CFC assay with purified phenotypic 
Lxn-/- and B6 HSPCs (Lin-c-Kit+ cells). If what we hypothesized is true, there will 
be less colonies formed with equal numbers of HSPCs from Lxn-/- mice than B6 
mice after mobilization. Because even though flow cytometric analysis showed 
more HSPCs are released to PB in Lxn-/- mice, most of progenitor cells are non-
functional. 
Many of the same adhesion molecules are expressed on both on stem 
cells and stromal cells. The overlapping expressions of these molecules (that 
bind to the same ligands or shared similar functions) provide redundancies in 
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expression and function34-36. This strategy ensures that a minor reduction in one 
or several adhesion molecules does not affect stem cell behavior and 
homeostasis. However, in our studies, microarray analysis identified an extensive 
list of adhesion molecules (involved in cell-to-cell and cell-to-ECM interactions) 
which were universally under-expressed. It is possible that small reductions in 
gene expression of many individual genes compromise HSPC retention and 
promote HSPC mobilization in Lxn-/- mice133. This hypothesis explains the 
observation that more HSPCs (phenotypically identified)  are released into blood 
circulation in Lxn-/- PB compared to B6. In clinical practice, the interactions 
between stem/progenitor cells and stromal cells are disrupted by G-CSF or other 
cytokines, resulting in the relocalization of HSPCs to the peripheral blood25-29. In 
this study, G-CSF administration manifests the defect (a compromised HSPC 
retention) and induces the release of significantly more HSPCs (phenotypically 
identified) into blood circulation. 
Among the adhesion molecules, thbs-1 is the most down-regulated. Its 
expression level was decreased 4-fold in Lxn-/- MPP population. The thbs-1 
protein is an adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix 
interactions133, 134. It is a critical part of the stem cell niche, and is involved in 
binding to other adhesion molecules such as fibrinogen, fibronectin, intergrin and 
collagen10. To further study the in vivo role of thbs-1 in regulating increased 
mobilization in Lxn-/- mice, we ectopically overexpressed thbs-1 in primitive 
hematopoietic cells. The cells overexpressing Thbs-1 will be tested for their 
retention capacity using in vitro and in vivo experiments. 
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In conclusion, the loss of Lxn in hematopoietic cells enhances their 
mobilization into peripheral blood system and results in a compromised retention 
capacity through down-regulating the adhesion molecules which involved in cell-
to-cell and cell-to-ECM interactions. 
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Figure 4.1 Flow cytometric analysis of mobilized HSPCs in PB of B6 and 
Lxn-/- mice.  
(A) and (B) Flow cytometric analysis demonstrating  the numbers of Lin
-
Sca-1
+
c-Kit
+ 
cells (HSCs), Lin
-
Sca-1
-
c-Kit
+ 
cells (HPCs) and Lin
-
c-Kit
+ 
cells (HSPCs) in the PB of 
unmobilized or mobilized B6 and Lxn-/- mice (n=4 for each group). * indicated a 
P<0.05 hereafter. 
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Figure 4.2 Mobilization of HSPC in B6 and Lxn-/- mice measured by CFU 
assay.  
(A) The frequency of CFCs in 10 uL PB in unmobilized or mobilized B6 and Lxn-/- 
mice (n=3 for each group). (B) The frequency of CFCs in spleen in unmobilized or 
mobilized B6 and Lxn-/- mice (n=3 for each group).  
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Figure 4.3 Adhesion capacities in HSPCs in B6 and Lxn-/- mice. 
 (A) Experimental design of the adhesion assay. BM cells from the unmobilized B6 
and Lxn-/- mice were added to wells containing confluent feeder cells. Non-adhesive 
cells were washed away after 2 hours and plates were scored at day 7. The 
frequency of adherent HPCs (washed) was normalized to the initial HPC frequency 
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(unwashed). (B) Percentage of adherent HPCs (the frequency of adherent HPCs 
normalized to the initial HPC frequency) (n=3 for each group). 
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Table 4.1 GSEA enrichment table of pathways altered in Lxn-/- MPP cells 
 
List of 5 top differentially expressed pathways from Lxn-/- MPP population.  The 
number of genes in each pathway, number of genes in the leading edge, and 
corresponding FDR q-value are listed as above.  
 
  
Name Size FDR q-value 
# of genes in leading 
edge 
Proteasome 18 0.004 14 
Cell-Communication  120 0.003 88 
Neuroactive-ligand-receptor 
222 0.003 147 
ECM-Receptor-interaction 
80 0.002 44 
Cell-cycle 95 0.19 79 
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Table 4.2 Gene expression profile of genes in Cell-to-ECM interaction 
pathways. 
Gene Contrast Gene Contrast Gene Contrast 
THBS4 -1.25 GP9 -1.25 ITGB7 -1.10 
COL5A2 -1.24 LAMA3 -1.15 ITGA10 1.0 
COL1A2 -1.26 ITGA2 -1.25 SV2B -1.10 
COL4A6 -1.23 COL11A2 -1.11 GP1BA -1.05 
FNDC5 -1.23 ITGB6 -1.12 TNR -1.0659 
ITGA7 -1.23 SV2C -1.11 SDC1 -1.10 
THBS1 -3.44 FNDC1 -1.1 ITGA8 -1.106 
SDC4 -1.25 ITGB8 -1.17 LAMA5 -1.04 
LAMA1 -1.18 FNDC3A 1.12 SPP1 1.04 
TNN -1.22 COL5A3 -1.12 THBS2 -1.04 
LAMB3 -1.18 LAMC3 -1.12 LAMB2 -1.03 
COL4A4 -1.21 CD44 1.12 SV2A -1.03 
ITGA2B -1.24 LAMA4 -1.10 FNDC4 -1.03 
LAMC2 -1.17 TNXB -1.13 CD47 1.02 
COL11A1 -1.19 ITGA6 1.12 ITGB3 -1.02 
LAMA2 -1.19 TNC -1.13 ITGA4 -1.02 
COL1A1 -1.20 COL6A2 -1.11 AGRN 1.02 
COL2A1 -1.19 ITGA3 -1.12 ITGA11 -1.01 
THBS3 -1.15 COL4A2 -1.10 SDC3 -1.02 
COL6A3 -1.17 GP5 -1.119 ITGB5 -1.01 
HMMR 1.25 ITGAV -1.11 DAG1 -1.01 
ITGA9 -1.31 LAMC1 1.1 SDC2 1.1 
VWF -1.15 ITGA1 -1.20 FN1 -1.0 
HSPG2 -1.14 COL4A1 -1.10 CD36 -1.1 
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 Table 4.2 continues 
CHAD -1.27 COL6A1 -1.10 GP9 -1.25 
COL5A1 -1.14 RELN -1.10 VTN -1.16 
 
80 genes in Cell-to-ECM interaction pathway have been listed above with their 
expression level altered in Lxn-/- MPP cells. Majority of the genes have been down-
regulated. 
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Table 4.3 Gene expression profile of genes in Cell-to-Cell interaction 
pathway. 
Gene Contrast Gene Contrast Gene Contrast 
THBS4 -1.25 COL2A1 -1.19 GJA3 -1.11 
COL5A2 -1.24 THBS3 -1.15 GJA5 -1.14 
COL1A2 -1.26 COL6A3 -1.17 LAMA4 -1.10 
KRT86 -1.30 VWF -1.15 GJA10 -1.14 
COL4A6 -1.23 KRT12 -1.15 TNXB -1.13 
KRT74 -1.20 CHAD -1.27 KRT15 -1.10 
THBS1 -3.44 KRT2 -1.14 ITGA6 1.12 
KRT75 -1.21 COL5A1 -1.14 GJC1 -1.11 
KRT31 -1.18 GJD2 -1.13 TNC -1.13 
KRT28 -1.2 VTN -1.16 LMNB1 1.1 
KRT24 -1.23 GJB6 -1.15 COL6A2 -1.1 
KRT84 -1.24 KRT40 -1.14 KRT35 -1.11 
GJA8 -1.18 KRT78 -1.12 KRT34 -1.10 
LAMA1 -1.18 LAMA3 -1.15 KRT20 -1.13 
TNN -1.22 KRT23 -1.20 GJB3 -1.13 
KRT9 -1.22 KRT33B -1.15 GJD4 -1.10 
DES -1.18 COL11A2 -1.11 COL4A2 -1.10 
GJB1 -1.18 KRT4 -1.15 KRT14 -1.12 
LAMB3 -1.18 KRT77 -1.13 GJC2 -1.10 
COL4A4 -1.21 KRT76 -1.15 KRT17 -1.10 
LAMC2 -1.17 KRT19 -1.15 KRT1 -1.10 
COL11A1 -1.19 GJD3 -1.11 KRT33A -1.10 
LAMA2 -1.191 KRT13 -1.14 KRT82 -1.10 
COL1A1 -1.12 KRT18 -1.24 LAMC1 1.10 
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table 4.3 continues 
DSC2 -1.18 COL5A3 -1.12 COL4A1 10 
KRT36 -1.17 GJA4 -1.10 DSG4 -1.10 
GJB5 -1.10 DSC1 -1.10 LMNA 1.10 
RELN -1.10 PRPH -1.10 KRT83 -1.04 
KRT72 -1.10 KRT39 -1.10 KRT6B 1.04 
GJB4 -1.10 KRT25 1.05 KRT73 -1.02 
VIM 1.10 TNR -1.10 DSC3 -1.02 
KRT32 -1.10 KRT8 1.05 NES -1.02 
IBSP -1.10 KRT79 -1.04 ACTB 1.01 
DSG2 -1.12 KRT27 -1.04 KRT5 -1.01 
COL3A1 -1.10 LAMA5 -1.04 KRT6A 1.003 
GJA1 1.10 SPP1 1.04 FN1 -1.004 
COMP -1.10 KRT7 -1.04 KRT16 1.003 
LMNB2 1.10 THBS2 -1.04 KRT71 -1.001 
DSG3 -1.10 LAMB2 -1.03 KRT10 -1.00009 
 
120 genes in Cell-to-Cell communication and interaction pathway have been listed 
above with their expression level altered in Lxn-/- MPP cells. Majority of the genes 
have been down-regulated. 
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CHAPTER 5: Latexin is Down-regulated in Hematopoietic Malignancies and 
Restoration of Expression Inhibits Lymphoma Growth 
 
5.1 Abstract 
Latexin is a negative regulator of hematopoietic stem cell number in mice. 
Its dysregulated expression in other tumors led us to hypothesize that latexin 
may have tumor suppressor properties in hematological malignancies. We found 
that latexin was down-regulated in a variety of leukemia and lymphoma cell lines 
as well as in CD34+ cells from the blood and marrow of patients with these 
malignancies. 5-aza-2’-deoxycytodine treatment and bisulfite sequencing 
revealed hypermethylation of latexin promoter in tumor cells. Retrovirus-
mediated latexin overexpression in A20 mouse lymphoma cells inhibited their in 
vitro growth by 16 fold and in vivo tumor volume by 2 fold. Latexin caused growth 
inhibition of lymphoma cells by significantly increasing apoptosis through the 
down-regulation of anti-apoptotic genes Bcl-2 and Pim-2. The molecular 
mechanism underlying latexin-mediated tumor inhibition was not through its 
canonical carboxypeptidase inhibitor activity. These results are consistent with a 
tumor suppressor role for latexin and suggest that latexin may have clinical 
efficacy in the treatment of malignancies.  
5.2 Introduction 
Both solid and liquid tumors are now understood to originate from the 
malignant transformation of resident adult stem and progenitor cells135, 136. 
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Nowhere is this paradigm better established than in leukemia, yet events causing 
neoplastic conversion remain poorly understood137. We identified latexin (Lxn) as 
a novel, homeostatic regulator of the size of the hematopoietic stem cell 
population in mice93. The stem cell pool size was inversely related to quantitative 
Lxn expression at both the levels of transcript and protein. We found that 
population size was influenced by Lxn in a stem cell-autonomous manner, and 
acting through the concerted mechanisms of self-renewal and apoptosis, which 
were decreased and increased, respectively, by Lxn abundance93. Thus, Lxn acts 
as a brake on the expansion of stem cell population. Unrestrained stem cell 
expansion carries with it the risk of mutations, genomic instability and 
carcinogenesis. We therefore hypothesized that Lxn expression patterns in stem 
and progenitor cells may act as a tumor suppressor by inhibiting stem and 
progenitor cell proliferation, influencing the crucial steps toward malignancy.  
Lxn was primarily studied in the nervous system, involving the 
specification of cortical brain regions during development89, 138-141, as well as the 
speed of nerve transmission in adult peripheral nervous systems90. Lxn was 
found to be involved in the inflammatory response in macrophages owing to its 
paired cystatin-like domains142. It was detected in mast cells associated with a 
unique type of intracellular granule distinct from histamine-containing secretory 
granules and lysosomes91. Lxn has about 30% sequence homology, but much 
greater structural homology, with tazarotene-induced gene 1 (TIG1) (or retinoic 
acid receptor responder 1, RARRES1), whose expression was down-regulated in 
an extensive list of tumor types in humans106, 142-145. Lxn and TIG1 are closely 
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linked genetically and may represent members of a family of functionally related 
genes. Moreover, Lxn was reported to be a TNF-responsive gene in human 
papillovirus-infected keratinocytes, suggesting that it may contribute to TNF-
mediated suppression of cervical cancer development146. A recent report 
revealed that Lxn was down-regulated in patients with gastric carcinomas, and 
overexpression or knockdown of Lxn inhibited or stimulated tumor growth 
respectively147. Decreased or absent Lxn expression was observed in several 
human leukemia and lymphoma cell lines148, as well as in malignant melanoma 
patients149. However, there is still lack of direct evidence for the cause-effect 
relationship between Lxn and hematopoietic malignancy. 
Gene silencing, especially of tumor suppressors, and inappropriate gene 
activation, especially of oncogenes, are common themes in carcinogenesis150. 
Both often occur through aberrant DNA methylation that is accentuated during 
aging151-156. A CpG-enriched region was identified in Lxn promoter and its 
hypermethylation was found in a variety of human gastric carcinoma cell lines147.  
Promoter hypermethylation of TIG1 was also associated with its silencing in 
tumor cells 106, 145. However, it is not known whether Lxn expression is regulated 
by promoter methylation in hematopoietic malignancy.  
Molecular mechanisms underlying the role of Lxn in regulating 
hematopoiesis has not been determined yet. Lxn protein binds to 
carboxypeptidase A (Cpa) and inhibits its enzymatic activity, indicating that Lxn 
regulates protein degradation and metabolism148. Lxn was highly expressed in 
mast cells and its expression was further enhanced by LPS, indicating its 
111 
potential function in inflammation142. Proteomic analysis on Lxn knock-out 
hematopoietic cells revealed that Lxn deletion reduced the abundance of multiple 
cellular proteins, especially those involving cell-stroma interaction, such as N-
cadherin, Tie2, and Roundabout 4148. Ectopic expression of Lxn in gastric cancer 
cell lines led to the differential expressions of several cancer-related genes, 
including Maspin, WFDC1, SLPI, S100P, and PDGEFB 147, although none of 
them are overlapped with previously mentioned proteomic results. A recent study 
revealed ATP/GTP binding protein-like 2 (AGBL2) as a novel binding partner of 
TIG1. The interaction between TIG1 and AGBL2 regulates the microtubule 
tyrosination cycle, which is implicated in tumorigenesis, stem cell differentiation 
and development157. Lxn thus may have the similar mechanisms as TIG1 to 
regulate hematopoiesis.   
Here, we provide evidence obtained from a variety of lymphoma and 
leukemia cell lines, as well as from primary cells from patients with these 
diseases, that Lxn expression is almost universally absent or significantly 
reduced from that of normal stem and progenitor cells. Moreover, treatment with 
a de-methylating agent at least partially restores Lxn expression in a variety of 
tumor cell lines, and methylation level of the CpG island in the Lxn promoter 
region is inversely associated with its expression. Perhaps most importantly, we 
show that when Lxn expression was re-initiated ectopically in two lymphoma cell 
lines using a retroviral expression vector, their growth, both in vitro and in vivo, 
was significantly blunted. We further show that Lxn inhibits lymphoma cell growth 
by significantly increasing apoptosis through the down-regulation of anti-
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apoptotic genes and that its anti-tumor activity is mediated via mechanisms 
unique from its canonical inhibition of carboxypeptidase A. These results 
demonstrate that Lxn plays a functional role in tumor cell growth and introduces 
an unexplored pathway potentially important to cancer treatment in patients.  
5.3 Material and Methods 
5.3.1 Animal 
Young 8-to 12- week old female C57BL/6 (B6) and 7-week old female 
BALB/c mice were purchased from the Jackson Laboratories (Bar Harbor, ME). 
Mice were kept in the animal facilities of the University of Kentucky under 
pathogen-free conditions according to NIH-mandated guidelines for animal 
welfare. They were fed with acidified water and food ad libitum.  All animal work 
in this study was approved by Institutional Animal Care and Use committee 
(IACUC) at the University of Kentucky (Identification number: 2010-0753) 
5.3.2 Leukemia cell lines 
Nine human leukemic cell lines (K562, Molt4, CCRF-CEM, J45.01, Jurkat, 
U937, HL-60, KG-1 and SupB15) and two mouse lymphoma cell lines (WEHI-231 
and A20) were included in our study. Human leukemic cell lines were purchased 
from American Type Culture Collection (ATCC) (Manassas, VA). Mouse 
lymphoma cell lines are gifts from Dr. Bondada 158. The leukemia cell lines were 
maintained in IMDM supplemented with either 10% (K562) or 20% (KG-1, HL-60 
and Sup-B15) fetal bovine serum (FBS), or RPMI medium with 10% FBS, 10mM 
113 
Hepes (Molt4, CCRF-CEM, J45.01, Jurkat and U937), 0.05mM 2-
mecaptoethanol, 80 U/mL penicillin, and 80mg/mL streptomycin. The cells were 
incubated in a humidified atmosphere of 5% CO2 in air at 37°C.  
5.3.3 Isolation of CD34+ cells  
Primary AML cells were obtained from the peripheral blood and bone 
marrow of patients at the Markey Cancer Center and Northwestern University. 
Normal bone marrow was obtained as discarded material following pathologic 
analysis, surgical marrow harvest, or from the National Disease Research 
Interchange (NDRI). CB was obtained from patients at the University of Kentucky 
Obstetrics Department or from the NDRI. All tissues were obtained with the 
approval of the respective institutional review boards and appropriate informed 
consent (confirmation number is 11-0315-F3R from University of Kentucky). 
Some samples were collected from Northwestern University and transferred to 
University of Illinois at Urbana-Champaign with approval of Material Transfer 
Agreement (MTA). We processed 9 normal and 9 leukemia and lymphoma 
samples, the age and disease type of each sample are described in the figure 
5.5 legends. Marrow and blood cells were depleted of erythrocytes by 
suspending in 150 mM NH4Cl plus 10 mM NaHCO3 for 5 minutes, followed by 2 
washes with phosphate-buffered saline (PBS). Blood cells were subjected to 
Ficoll-Paque (Pharmacia Biotech, Piscataway, NJ) density gradient separation to 
isolate the mononuclear white blood cell compartment. Resulting leukocytes from 
marrow or blood were then used for immunoaffinity selection and flow cytometric 
sorting. For CD34+ cell selection, the Miltenyi immunoaffinity device (VarioMACS) 
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was used according to the manufacturer's instructions (Miltenyi Biotech, Auburn, 
CA), and further purified by immune-staining with anti-CD34 antibodies 
(Pharmingen, San Diego, CA) and sorting in a triple-laser FACSVantage flow 
cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA). In 
some cases, leukocytes were cryopreserved at a concentration of 5 x 107 
cells/mL in freezing medium consisting of Iscoves modified Dulbecco medium 
(IMDM), 40% FBS, and 10% dimethyl sulfoxide (DMSO).  
5.3.4 Quantitative real-time PCR  
To measure the expression of Lxn in leukemic cells, quantitative real-time 
PCR was performed. Identical numbers (200,000) of cells were used for total 
RNA extraction using RNeasy Mini kit (QIAGEN, Valencia, CA) according to the 
manufacture’s instruction. Isolated total RNA was reverse transcribed into cDNA 
using random hexamers in a TaqMan® reverse transcription solution (PN 
N8080234) and stored at -20ºC. In real-time PCR reactions, primer and probe 
mix for LXN (human and mouse) were purchased from Applied Biosystems 
(Foster city, CA, USA). TaqMan® human glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was served as an endogenous control to normalize 
LXN expression. PCR reactions were set up according to manufacturer’s 
instructions using TaqMan® universal PCR master mix  (PN 4304437). Analyses 
of gene expression were performed in single reporter assays in an ABI PRISM 
7700 sequence detection system (PE Biosystems, Foster city, CA, USA).  
RT2 Profiler Apoptosis PCR Array (PAMM-012Z, QIAGEN) was performed 
according to the manufacturer's instructions. cDNAs was prepared from A20 cells 
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infected with empty or lxn expression vectors with RT2 First Strand cDNA Kit (C-
03, QIAGEN) and added to RT2 qPCR master mix (PA-012). The mixture was 
aliquoted across the PCR array which contains 84 apoptosis-related genes. 
Gene expression and quantification was performed in an ABI PRISM 7700 
sequence detection system, and data was analyzed with using web-based 
software (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). The 
genes with more than 2-fold change in expression and showing statistically 
significant (p<0.05) were chosen for candidate gene. 
5.3.5 Western blots 
Cell samples were lysed at a concentration of 2x107 cells/ml in a protein 
lysis buffer containing: 10mM Tris pH7.5, 50mM NaCl, 30mM sodium 
pyrophosphate, 50mM NaF, 5µM ZnCl2 and 1 % Triton X-100, 2.8ug/ml aprotinin 
(Sigma-Aldrich; St. Louis, MO), 1mM phenylmethylsulfonyl fluoride (Sigma), 1mM 
sodium vanadate (Na3VO4) 1ug/ml pepstatin, and 1µg/ml leupeptin (Oncogene 
Research, MA, USA). Lysate was incubated on ice for 30 minutes, and then 
centrifuged at 15,000 x g for 10 minutes to remove debris. The resulting 
supernatant was then aliquoted and stored at -80°C. For Western blot, protein 
lysates were thawed and mixed with running buffer and a reducing agent (Novex, 
San Diego, CA, USA, per manufacturer’s instructions) and heated at 95°C for 5 
minutes. Samples were then analyzed by denaturing PAGE (Novex, 10% bis-Tris 
gel) using the equivalent of 4x105 cells per lane. Following electrophoresis, 
samples were electro-transferred onto immunobilon-P membranes (Millipore, 
Bedford, MA, USA), which were subsequently blocked and probed with 
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polyclonal rabbit anti-LXN Ig-G antibody at a 1:3000 dilution. This antibody was 
generated from the Lxn-specific amino acid sequence CKHNSRLPKEGQAE at 
the carboxyl terminus, and was produced by Bethyl Laboratories, Inc. 
(Montgomery, TX). The antibody for detection of human LXN was purchased 
from Abcam Inc. (Cambridge, MA) and used at 1:2000 dilution. The antibodies for 
apoptotic proteins, Bcl-2, Bcl-xl, Bax, Bad (Santa Cruz Biotechnology) were 
provided by Dr. Bondada. The antibody for Pim-2 was purchased from 
eBioscience (San Diego, CA). Primary antibodies were detected using alkaline 
phosphatase-conjugated secondary antibodies (Santa Cruz Biotechnology) and 
electro-chemifluorescent (ECF) reagent (Pharmacia Biotech) according to the 
manufacturer’s instructions. Blots were visualized using a Molecular Dynamics 
STORM 860 system and Imagequant Software. Following the detection and 
quantification of anti-LXN antibody, immunobilon-P membrane was sequentially 
stripped in 40% methanol and the buffer containing 100mm ß-mercaptoethanol, 2% 
sodium dodecyl sulfate and 62.4mM Tris-HCl to remove ECF reaction product 
and antibodies, respectively. The stripped membrane was re-probed with anti-
actin antibody (Sigma) at 1:500,000 dilution and detected as described previously. 
5.3.6 Genomic bisulfite sequencing 
To investigate the methylation pattern of Lxn promoter, CpG island 
analysis in the upstream sequence of Lxn open reading frame. Nucleotide 
sequence of Lxn in upstream region (–1000 bp) and the first 3 exons (+373bp) 
was obtained from Ensembl database (www.ensembl.org) with ID number 
ENSG00000079257. CpG island search using CpG island searcher website 
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(http://www.uscnorris.com/cpgislands2/cpg.aspx) showed a 252bp region (–
208bp to +44bp) in upstream of Lxn sequence enriched for CpG repeats. The 
criteria of 5 CpG island is: GC content >50%, ratio of CpG to GpC > 0.6 and 200 
bp of minimum length. Genomic DNAs were isolated using AquaPure Genomic 
DNA kit (Bio-Rad, Hercules, CA) and modified by sodium bisulfite using EpiTect® 
Bisulfite kit (QIAGEN, Valencia, CA). For the Lxn promoter methylation study, we 
designed primers that could amplify a 423bp fragment in the upstream region of 
Lxn containing CpG island. The forward primer sequence is 5’ 
GTTGGTGTTTGATAAGTATGTGG 3', and the reverse primer sequence is 5’ 
TTTAACCTTCTACACCTCAAACAC 3’. The annealing temperatures for primers 
were 52°C for 2 minutes. Hot-start PCR with a total cycle number of 30 was used 
in all PCR amplifications. Denaturation and extension cycles were maintained for 
95 °C, 30 seconds and 72 °C, 1 minutes respectively. The amplified fragments 
were cloned into the pCR2.1-TOPO vector using TOPO TA Cloning Kit 
(Invitrogen Carlsbad, CA) and sequenced (MWG Technology) (n 3 clones for 
cell line and n 8 clones for primary cells). 
5.3.7 5-aza-2’-deoxycytidine treatment 
To examine the correlation of promoter hypermethylation and Lxn gene 
expression, the leukemia cell line, shown to have a lack or decrease of Lxn 
expression, was subject to 5-aza-2’-deoxycytidine treatment. Cells were plated 
with 2uM 5-aza-2’-deoxycytidine (Sigma-Aldrich; St. Louis, MO) and incubated 
for 4 days. The medium and the drug were replaced every 24 hours and cells 
were harvested for RNA and DNA extraction 4 days after treatment.   
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5.3.8 Infection of WEHI231 and A20 cells with Lxn expression vector 
Cloning of the mouse Lxn gene into Sfbeta 91 retroviral vector and 
production of viral supernatant were performed exactly as described previously93. 
WEHI-231 and A20 cells were infected by 10ml viral supernatant at a density of 
1x106 cells per 10cm plate along with 4 µg/ml of polybrene for 48 hours. The 
infected cells (GFP+ cells) were sorted and expanded in culture medium. The 
expanded GFP+ population, if not used immediately, was cryopreserved at a 
concentration of 1 X 107 cells/mL in freezing medium consisting of 80% fetal 
bovine serum, and 20% dimethyl sulfoxide (DMSO).  
5.3.9 Measurement of growth of retrovirally-transduced tumor cells 
Sorted GFP+ A20 cells over expressing Lxn or Sfbeta 91 empty vector 
were counted on a hemacytometer using trypan blue dye exclusion and 500,000 
cells were seeded into 25cm2 tissue culture flask in 4mls media. Cells were 
incubated in a humidified atmosphere of 5% CO2 in air at 37°C and subsequently 
counted on days 3, 8, 12, 16 and 20. At each time point, cells were split and 
maintained at a concentration of 500,000 cells per 4 ml media. The cumulative 
cell number was calculated from the cell counts and the dilutions made at each 
culture split. FACS analysis was also performed at each time-point to measure 
the percentage of GFP+ cells. For the in vivo measurement of tumor cell growth, 
various numbers (5,000; 25,000; 50,000 and 100,000) of GFP+ A20 cells over 
expressing Lxn or Sfbeta 91 empty vector were injected in a 50µl bolus 
subcutaneously in the shaved flank of BALB/cJ mice given 3.0 Gy of gamma 
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radiation 4 hrs. prior. Lymphomas were detectable by palpation 10-12 days post-
injection and all three dimensions of tumors were measured blind with calipers on 
days 12, 14, 16, 19, and 21. The same individual made the measurements from 
day-to-day without knowing the treatment regimen the mice received. At day 21, 
host mice were euthanized, the lymphomas were excised, and single cell 
suspensions were made of each to determine the fraction of tumor cells 
expressing GFP. 
5.3.10 Cell cycle and apoptotic analysis  
The culture of GFP+ A20 cells was maintained as described above. At 
each time-point, cell cycle analysis was measured by BrdU labeling using BrdU 
Flow Kit (Pharmingen, San Diego, CA) according to the manufacturer’s 
instruction. 10ul of BrdU solution (1mM) was added to 1x106 cells in 1 ml culture 
medium and incubated for 1 hour. The cells were fixed and permeabilized by 
Cytofix/Cytoperm Buffer and treated with 30ug DNase for 1 hour at 37oC. After 
washing with Perm/Wash buffer, cells were stained with PE-conjugated anti-BrdU 
antibody for 20 minutes at room temperature, washed and 20 ul of 7-AAD was 
added. The cells were analyzed by flow cytometry on Facscan (Becton Dickinson 
Immunocytometry Systems, San Jose, CA). 
5.3.11 Immunohistochemstry of A20 cells treated with potato carboxypeptidase 
inhibitor (PCPI)  
PCI was purchased from Sigma-Aldrich Co. (St. Louis, MO). FITC labeling 
of PCI was performed by using FLUOROTAGTM FITC CONJUGATION KIT 
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(Sigma-Aldrich) according to manufacturer’s instruction, and was used to treat 
A20 cells for fluorescence internalization assays. Cells are cultured on 22x22mm 
microscope cover glasses (Fisher Scientific Co., Pittsburgh, PA) in media as 
described above. Cells were fixed onto cover glasses with 1:1 methanol:acetic 
acid and washed 3 times by PBS. Cells were incubated with FITC-conjugated 
PCI at a concentration of 30ug/ml at 37oC for 30 minutes, washed and stained 
with phycoerythrin (PE)-conjugated B220 and DAPI. The cover glass coated with 
A20 cell monolayer was flipped immediately and sealed onto glass slide.  The 
image was taken with a Zeiss Axiovert- 200 microscope using a high-resolution 
Zeiss digital camera (Carl Zeiss Inc., Thornwood, NY) 
5.3.12 Culture of A20 cells with potato carboxypeptidase inhibitor 
To determine the effects of PCPI on A20 cell growth, A20 cells were 
seeded at a density of 6x105/ well in 6-well plates, cultured overnight before the 
addition of 0, 5, 15, 30 or 60ug/ml PCI. The cells were fed every 2 days with 
fresh medium (as above) containing the respective concentration of PCI, and 
viable cells were counted on a hemacytometer using trypan blue dye exclusion. 
Cells were split according to cell population size to maintain a cell concentration 
of 2-5 x 106/ml and cultures were maintained for 12 days. The cumulative cell 
number was calculated from the cell counts and the dilutions made at each 
culture split.  
5.3.13 Statistical analysis  
Data were analyzed by either student t-test assuming unequal variance 
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with P < 0.05 (two-tail), or a one-way ANOVA. 
5.4 Results 
5.4.1 Loss of Lxn expression in malignant cells 
We first determined Lxn mRNA abundance in tumor cell lines by 
quantitative real-time PCR (Fig. 5.1A). Compared with normal primitive 
hematopoietic cells, Lxn mRNA expression was completely absent in a majority 
of tested leukemic lines, including K562, Molt4, CRF-CEM, J45.01, Jurkat and 
U937, and was significantly diminished in HL-60, KG-1 and SupB15 cell lines. 
LXN protein expression was also tested in all samples using Western blotting 
and nearly identical results were obtained in tested cell lines (Fig. 5.1B). Our 
results are consistent with those previously reported148 and include additional 
leukemia and lymphoma cell lines. 
5.4.2 Aberrant promoter hypermethylation of Lxn in hematopoietic 
malignancy 
To assess whether the loss or decrease of Lxn expression in malignant cell lines 
resulted from promoter hypermethylation, methylation of the 5’ CpG island of Lxn 
gene surrounding its transcriptional start site was determined by genomic bisulfite 
sequencing. The CpG island spans from within the canonical 5’ promoter (-208nt) to 
the transcription start site (+1nt), and extends through the entire first exon (+44nt). 
There are 15 CpG dinucleotides within this region (Fig. 5.2A). The CpG island 
identified here is not exactly same as the one reported previously, this may be due to 
the different criteria we used for defining this region. Figure 2B depicts the 
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quantitative variation in methylation for each CpG site among nine tumor cell lines. 
Almost complete methylation was seen in J45.01, U937, Jurkat, Molt4 and CCRF-
CEM (>90%) lines, which commensurately showed an absence of Lxn expression. 
Scattered methylated CpG sites were found in K562, KG-1 and SupB15 lines, which 
were linked to the weak expression of Lxn. Surprisingly, although HL-60 had very low 
Lxn expression, we found that none of the CpG sites were methylated. This is 
probably due to other epigenetic mechanisms, such as histone deacetylation of 
latexin promoter in HL 60 cells  
5.4.3 Reactivation of Lxn expression with demethylation reagent treatment 
To test the hypothesis that Lxn promoter hypermethylation might be 
involved in the loss of expression in leukemia and lymphoma cell lines, we 
studied the effect of 5-aza-2’-deoxycytidine, a DNA demethylating reagent, on 
Lxn expression (Fig. 5.2C). After treatment with 2 uM 5-aza-2’-deoxycytidine for 4 
days, Lxn gene expression was reactivated in cell lines completely lacking Lxn 
expression prior to treatment (K562, Molt4, CCRF-CEM, J45.01, Jurkat and 
U937), and was significantly up-regulated in HL-60, KG-1 and SupB15 lines. The 
up-regulation of Lxn by 5-aza-2’-deoxycytidine in HL60 cells, which shows no 
hypermethylation of CpG sties (Fig. 5.2B), might be because the demethylation 
of other DNA sequences induces chromatin remodeling, thus exposing Lxn 
promoter for the transcriptional initiation.  
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5.4.4 Suppression of growth of mouse lymphoma cell lines in vitro and in vivo 
following ectopic Lxn expression 
To determine a correlative or causative relationship between Lxn 
expression and tumor development, we next asked whether or not the re-
initiation of Lxn expression affected the growth rate of malignant cells in vitro and 
in vivo. To that end, we ectopically expressed Lxn, using a retroviral expression 
vector containing green fluorescent protein (GFP) marker, in the mouse BALB/c-
derived A20 B lymphoma cell line, which lacks Lxn expression (Fig. 5.3C). The 
controls are A20 cells either un-infected or infected with empty vector. The GFP 
positive A20 cells were purified by flow cytometric cell sorting, and their growth 
was determined in vitro and in vivo.  
Fig. 5.3 shows the potent effects of Lxn expression on inhibiting tumor 
growth in vitro and in vivo. Fig. 5.3A shows that cultures of A20 cells infected with 
the Lxn expression vector contained only about half the number of cells at day 3 
as compared to A20 cells infected with the control (empty) vector or uninfected 
control cells (A20 control). The growth suppression by Lxn overexpression was 
exponentially amplified during subsequent days of culture and by day 20 nearly 
16 fold less tumor cells were present in Lxn-overexpressing group than in control 
cultures (right panel). Fig. 5.3B shows that the fraction of GFP+ cells remained at 
90-100% throughout the 20 days of culture in both the Lxn vector- or control 
vector-infected cells. Fig. 5.3C shows that at day 20 of culture neither uninfected 
A20 cells nor A20 cells infected with the control (empty) vector expressed 
detectable Lxn protein, whereas in the Western blot a strong Lxn band was 
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evident in lysate of cells infected with the Lxn vector (upper band). LXN protein 
level at day 0 of culture in these cells is nearly identical to that at day 20 (data not 
shown). In a separate series of experiments, we have found a similar growth 
reduction in vitro when Lxn was ectopically expressed in WEHI231 lymphoma 
cells (data not shown). 
Fig. 5.3D shows a compilation of two independent experiments in which 
ectopic Lxn expression suppressed the growth of A20 cell in vivo. 100,000 GFP+ 
A20 cells infected with either the Lxn expression vector or the GFP only control 
vector, or uninfected A20 cells, were injected subcutaneously into the flanks of 
BALB/c mice. Beginning at day 12 when tumors were first palpable, the Lxn-
expressing cells caused significantly smaller tumors (filled circles; P<0.005). By 
day 21 when the experiments were terminated, the tumors in the Lxn vector-
injected group averaged only 40% of the volume of tumors in the other two 
control groups (P<0.05, n=12 in each group). At day 21, we determined the 
fraction of tumor cells expressing GFP and Fig. 5.3F shows that virtually all of the 
tumor cells in the Lxn and control vector groups were GFP+. More to the point, 
Western blots confirmed strong expression of Lxn as in the cells analyzed after 
20 days in culture (Fig. 5.3C). Thus, the reduction in tumor growth was due to 
durable Lxn expression in the tumor cells themselves. 
To explore the effects of cell dose on tumor size and latency before being 
palpable, we ejected graded doses of Lxn-expressing or control A20 cells (Fig. 
5.3E) to BALB/c recipient (n=4/group). At the 5,000 and 25,000 inoculum sizes, 
the Lxn-expressing cells not only resulted in more impressive suppression of the 
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size of tumors than with the 100,000 cell inoculum in Fig. 5.3D, but resulted in 
delayed onset of measurable-sized tumors. At day 21, the reduction in tumor size 
caused by ectopic Lxn expression was 83% and 63% at the 5,000 and 25,000 
cell doses, respectively. Host animals were necropsied for evidence of gross 
metastases to spleen, thymus and liver. No evident tumors were found in any of 
the treatment groups. Similarly, flow cytometry detected no GFP+ cells in these 
anatomical sites (data not shown).  
5.4.5 Lxn inhibits tumor cell growth through increasing apoptosis but not via 
its canonical function 
As we previously reported in our normal hematopoietic stem cell studies, 
high Lxn expression is associated with increased apoptosis and decreased 
proliferation. To determine if these mechanisms were applied to our results with 
tumor cells, we next measured these two parameters in vector-infected A20 cells 
throughout 21 days of culture. As shown in Fig. 5.4A, flow cytometric analysis of 
cells stained with BrdU and 7AAD allows for the discrimination of cell subsets 
that are apoptotic (A), necrotic (N) or reside in G0/G1, S and G2/M phase of cell 
cycle. By day 5 of culture, 10 fold more Lxn-expressing tumor cells were 
undergoing apoptosis than control cells (10.6% vs 1%). No significant differences 
in the proliferation and the numbers of necrotic cells were observed between 
Lxn-overexpressing and control cells (data not shown). These results point to 
apoptosis as the major cellular mechanism in Lxn-mediated tumor suppression. 
We next investigated the molecular mechanisms underlying Lxn-induced 
apoptosis. We performed apoptosis pathway-specific PCR arrays in A20 cells 
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infected with either empty or Lxn-expressing vectors. We found that 17 out of 84 
apoptosis-related genes were differentially expressed in Lxn-overexpressing cells, 
and majority of them (15 genes) were down-regulated (data not shown). We 
specifically examined several well-known apoptotic genes, including Bcl-2, Pim-2, 
Bcl-xl, Bax, and Bad, and plotted their expression in Fig. 5.4B. Two anti-apoptotic 
genes, Bcl-2 and Pim-2, were down-regulated by at least 3-fold in Lxn-
overexpressing cells (left panel) as compared to the control, whereas pro-
apoptotic genes, including Bax and Bad, did not show any change in their mRNA 
levels. Western blots of these proteins observed the similar reduction in Bcl-2 
and Pim-2 (all three isoforms) but not in Bcl-xl, Bax and Bad in Lxn-
overexpressing A20 cells (right panel), which is consistent with PCR array result. 
Thus our data indicate that Lxn-induced apoptosis in A20 cells is mainly through 
the down-regulation of anti-apoptotic regulators, such as Bcl-2 and Pim-2. 
A well-known function of Lxn is its role as the sole carboxypeptidase A 
(CPA) inhibitor in mammalian cells. There are six Cpa genes (1-6) in this family. 
In order to test whether or not the suppressive effect of ectopic Lxn expression 
on the growth of A20 and WEHI231 cells was due to its canonical inhibitory 
activity, we carried out the following experiments. We first determined which Cpa 
genes are enriched in hematopoietic stem/progenitor cells. By searching our 
gene expression profile of hematopoietic stem/progenitor cells (unpublished 
data), we found that Cpa3 is the only gene highly expressed in hematopoietic 
cells (Tab. 5.1).  Next, we tested Cpa3 expression in A20 cells that were 
uninfected, or infected with empty or Lxn expression vectors, and found that it 
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was not expressed in any type of these cells (Fig. 5.6). Last, we treated A20 and 
WEHI cells with potato carboxypeptidase A inhibitor (PCPI), a 39 amino acid 
protein which strongly inhibits mammalian CPA, at a series of concentrations 
ranging from 5 to 60ug/ml of culture medium. As seen in Fig. 5.4C, none of the 
concentrations had any effect on the growth patterns of the tumor lines, despite 
the continuous presence of PCPI for 12 days of culture. To rule out the possibility 
that PCPI failed to inhibit tumor growth because it did not enter the cells, we used 
fluorescein isothyiocyanate (FITC) to label PCPI in cells. Fig. 5.4D shows A20 
cells following a 30 min incubation with labeled PCPI (30ug/ml of culture 
medium). The three-color micrograph shows PCPI in green (FITC), the nucleus in 
blue (DAPI), and the B220 lymphoid cell surface marker in red (phycoerythrin, 
PE). It is apparent that PCPI is plentiful in the cytosol but is not found in the 
nucleus. The doses of PCPI chosen for the above experiments were taken 
directly from a study in which the inhibitor was shown to inhibit the growth of 
pancreatic adenocarcinoma cells by directly interfering with the epidermal growth 
factor signaling pathway159. Maximal growth inhibition was achieved at 30-
50ug/ml. Thus, the mechanisms by which Lxn regulates both stem cell population 
size and lymphoma growth inhibition reside in a novel pathway involving 
apoptosis. 
5.4.6 Down-regulation of Lxn in primary leukemia and lymphoma cells 
Based on the strong evidence for the tumor suppressive function of Lxn in 
leukemia and lymphoma cell lines, we asked whether or not Lxn expression is 
altered in primary cells derived from patients with malignancies. We isolated 
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stem/progenitor-enriched CD34+ cells from bone marrow and blood cells in 
lymphoma and leukemia patients, as well as in normal donors. The patients 
included those with acute myeloid leukemia (AML), T cell pro-lymphocytic 
leukemia (T-PLL), plasma cell leukemia (PCL), acute T cell lymphoma (ATLL) 
and acute lymphoid leukemia (ALL, preB phenotype).  The normal CD34+ cell 
samples were derived from cord blood (CB) and young (31 and 35 years) and old 
(85 and 97 years) adults. Lxn mRNA expression, quantified by real-time PCR, 
was decreased by at least two-thirds in primary malignant CD34+ cells (Fig. 
5.5A). Quantification of LXN in CD34+ cells of all human normal and leukemic 
samples compiled to date is plotted in Fig. 5.5B. The result shows a significant 
decrease of LXN protein expression in malignant cells (P=0.03) even though Lxn 
expression at the protein level is more variable than that at the mRNA level. Two 
additional old samples in the normal control group contribute to this variation, 
which is consistent with the report that the number and functionality of HSCs in 
old individuals, perhaps stem cell regulatory gene(s), showed more dramatic 
variations as compared to their young counterparts160. In summary, these data 
indicate that Lxn dysregulation may be involved in human hematological 
malignancies. In the future study, it will be interesting to examine the expression 
of two anti-apoptotic genes, Bcl-2 and Pim-2, in patient samples to see whether 
or not they are up-regulated. 
5.5 Discussion 
Recently we found that Lxn is a natural regulator of hematopoietic stem 
cell population in mice by influencing self-renewal and apoptosis93. Lxn 
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expression in stem cells is inversely proportional to the size of the population in 
mice and thus acts as a negative regulator through cell-intrinsic mechanisms. 
The observation that low Lxn expression in hematopoietic cells was associated 
with increased replication led us to hypothesize that Lxn was down-regulated in 
malignancies with high proliferative rates and/or low apoptosis.  
Here, we show that Lxn is either not expressed or is strongly down-
regulated in a variety of leukemias and lymphomas. As a result of these findings 
and close linkage structurally and genetically with TIG1, we proposed that Lxn 
may similarly act as a tumor suppressor. Along with this proposal, there is 
expectation that manipulation of Lxn levels in malignant cells would alter their 
growth characteristics. Accordingly, two lymphoma cell lines in which Lxn 
expression was absent were infected with a Lxn expression vector. In one of the 
most significant findings of this study, we found that re-initiation of Lxn 
expression dramatically reduced their growth in vitro and in vivo. These results 
demonstrate that the level of Lxn expression is functionally related to both normal 
and malignant cell growth and, if the findings are true for human tumors, may 
provide an avenue for therapeutic intervention. Surprisingly, Lxn knock-out mice 
did not development leukemia nor lymphoma even though their hematopoietic 
stem cell pool was over-expanded and blast cells were detected in the peripheral 
blood148. These results suggest that Lxn may influence the crucial step in 
carcinogenesis161. It thus will be of great interest to introduce additional 
carcinogenetic “hits”, such as oncogenes or alkylating agents, to Lxn knockout 
stem cells to determine whether Lxn deletion will accelerate tumor development. 
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In addition, we observed that re-initiation of Lxn expression did not completely 
suppress tumor cell growth, suggesting that it would at best be a part of a multi-
drug regimen.  
We investigated the possible mechanisms by which ectopic Lxn 
expression may suppress growth of lymphoma cells and found increased 
apoptosis to be the major mechanism causing inhibition. Consistent with our 
study of normal hematopoietic cells, our recent findings indicate that high Lxn 
content is associated with more apoptotic cells, thus fewer stem cells 93. 
Apoptosis is controlled by the balance of both positive (pro-apoptotic) and 
negative (anti-apoptotic) signals. We found that Lxn-induced apoptosis is mainly 
through the down-regulation of anti-apoptotic genes, such as Bcl-2 and Pim-2. 
Decreased level of Bcl-2 allows other pro-apoptotic proteins such as BAX and 
BAK to aggregate, inducing cytochrome C release and caspase activation, and 
apoptosis. Dysregulation of Bcl-2 is implicated in a variety of hematopoietic 
malignancies. 124 Three Pim-2 protein isoforms are active kinases which 
phosphorylate pro-apoptotic protein BAD and dissociate its binding from Bcl-xL, 
resulting in the inhibition of Bad-induced cell death.162, 163 Enhanced expression 
of Pim-2 was detected in multiple B-cell lymphoma types164, T-cell lymphoblastic 
leukemia/lymphoma165, and acute myeloid leukemia166. Thus our studies identify 
Lxn as a novel regulator of the apoptotic pathway, in which it suppresses tumor 
survival through the down-regulation of Bcl-2 and Pim-2 anti-apoptotic factors. 
The well- known function of Lxn is the sole carboxypeptidase A inhibitor in 
mammals.91 Therefore, it was plausible that other carboxypeptidase A inhibitors 
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might mimic Lxn’s anti-tumor effects. A CPA inhibitor from potato tubers has been 
shown to be an effective inhibitor of mammalian CPA and was therefore chosen 
to test its anti-tumor properties. We found that it freely entered A20 lymphoma 
cells but did not have suppressive growth effects via apoptosis, irrespective of 
dose. Since CPAs are not expressed in A20 cells, we conclude that non-
canonical functions of Lxn were responsible, yet unknown intracellular functions 
of Lxn account for its anti-tumor effects. In addition, it is unlikely that tumor 
suppressive effect of Lxn is through the regulation of ABGL2-mediated 
microtubule tyrosination cycle, like TIG1, because we did not detect the 
expression of ABGL2 in hematopoietic cells (data not shown). These results are 
in line with findings of other investigations in which gene expression or protein 
abundance regulated by Lxn were not related to carboxypeptidase inhibition 147, 
148. Thus, the action of mode of Lxn in regulating normal and malignant 
hematopoiesis is not through its canonical CPA inhibitor activity. Future studies 
aimed at identifying direct targets, or downstream signaling pathways, of Lxn will 
be critical for our understanding of its function in normal and malignant 
hematopoiesis. 
Addressing the issue of why and how Lxn expression is down-regulated in 
tumor cells, we found that CpG dinucleotides in regulatory regions of the Lxn 
gene were methylated. Most human leukemia and lymphoma cell lines tested 
showed strong patterns of methylation involving most of the 15 CpG 
dinucleotides in Lxn promoter. This, in turn, led to a loss of gene expression that 
was at least partially reversible. When cell lines were treated with de-methylating 
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reagent, 5-aza-2’-deoxycytidine, Lxn expression was re-initiated or up-regulated. 
Thus, hypermethylation of the CpG island in the Lxn promoter may contribute to 
silencing or down-regulation of Lxn expression in leukemia and lymphoma cells. 
Ongoing studies will focus on the genetic and epigenetic regulation of Lxn 
transcription in cancer stem cells, with promise for improved targeted approaches 
for cancer prevention, diagnosis, and therapy. 
5.6 Acknowledgements 
I gratefully acknowledge Gary Van Zant, Dianna Howard, Kyle Rector, 
Carol Swiderski, Jason Brandon, Lawrence Schook, Jayesh Mehta, J. Scott 
Bryson, Subbarao Bondada, and Ying Liang for their contributions to this 
manuscript. I thank the technical assistance of Xian Gao in image capturing of 
immunocytochemstry staining, Barry Grimes in flow cytometry, and Hope 
Johnson and Paula Thomason for editing manuscript. 
 
 
 
 
 
 
 
 
 
133 
 
Figure 5.1. Decrease or loss of Lxn expression in leukemic and lymphoma 
cell lines.  
(A) Lxn mRNA expression in leukemia cell lines. Lxn mRNA level was measured 
by quantitative real-time PCR and shown as mean (± 1 SD) (n=12). Control is 
normal bone marrow (BM). (B) Lxn protein expression in leukemic cell lines 
measured by western blot. The blot (bottom) and their quantification (top) profiles 
demonstrate the absent or weak expression of LXN protein in leukemic and 
lymphoma cell lines. Actin was used as the internal control.  
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Figure 5.2. Hypermethylation of Lxn promoter CpG sites in leukemic cell 
lines.  
(A) CpG-enriched region in Lxn promoter. Sequence from 1500 base pairs 
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upstream regulatory region to the first three exons was analyzed for CpG-
enriched sites (top). A CpG island with 252 base pairs (bps) length was identified. 
The transcription starting site is indicated. Each filled circle represents a CpG 
dinucleotide, and there are 15. (B) Bisulfite sequencing for Lxn promoter CpG 
island methylation analysis in leukemic cell lines. Files are each of the 15 CpGs 
and ranks are replicate clones sequenced for each CpG (n=3). Open circles 
indicate unmethylated CpG (n=3) dinucleotides.  Filled circles indicate 
methylated CpG dinucleotides. The methylation content was quantified by 
dividing the number of methylated CpGs with total numbers of analyzed CpGs. 
(C) Restoration or up-regulation of Lxn expression by 5-aza-2’-deoxycytidine. Lxn 
mRNA was measured by quantitative real-time PCR in leukemic and lymphoma 
cell lines exposed with or without 2uM 5-aza-2’-deoxycytidine for 4 days. 
Expression levels were normalized to endogenous control, Gapdh. Results 
shown are mean SD of 12 replicates from 3 independent experiments. 
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Figure 5.3. Overexpression Lxn suppresses growth of A20 lymphoma cell 
lines.  
(A) In vitro growth inhibitory effects of Lxn overexpression on A20 cells. A20 cells 
uninfected (A20 control) or infected with empty (vector control) or Lxn-containing 
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vector (Lxn vector) were cultured for 20 days and counted by the trypan blue 
exclusion method. The absolute cell numbers at indicated time-points (X axis) 
were represented as log scale (Y axis) and were shown in left panel. The relative 
tumor growth in Lxn-overexpression A20 cells to controls was shown in the right 
panel. One representative experiment out of 3 independent ones is shown. (B) 
Proportion of GFP+ A20 cells infected with empty (light grey column) and Lxn-
containing vector (black column) throughout 20 days of culture. Flow cytometric 
analysis was performed to detect GFP signal. (C) Western blot analysis with LXN 
antibody in total protein lysate from A20 cells at day 20 culture showing durable 
LXN overexpression. (D) In vivo tumor formation and growth with injection of 
100,000 A20 cells. A20 cells were subcutaneously injected and tumor growth was 
monitored and measured by all three dimensions of tumors (Y axis) on days 
indicated on X axis. Shown is the compilation of 2 independent experiments with 
 SD (n=12). The statistical significance is represented by * (p<0.005) and ** 
(p<0.05). (E) In vivo tumor formation and growth with injection of graded doses of 
A20 cells. Graded doses of A20 cells (X axis) were subcutaneously injected and 
tumor growth was monitored and measured in all three tumor dimensions (Y axis) 
on days indicated on Z axis. Unfilled columns represent A20 cells infected with 
empty vector and filled columns represent cells with Lxn-containing vector. A 
representative experiment is shown (n=4/group). (F) The fraction of GFP-
expressing A20 cells in tumors biopsied at 21 days. Single tumor cell 
suspensions were made on day 21 post injection and subject to flow cytometric 
analysis for GFP-expressing cells.    
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Figure 5.4. Ectopic Lxn expression increases apoptosis of A20 cells.  
(A) Flow cytometric analysis of cell cycle and apoptosis in cultured A20 cells. A20 
cells without (A20 control) or with empty (vector control) or Lxn-containing vector 
(Lxn vector) were cultured for 21 days. BrdU and 7AAD staining and flow 
cytometric analysis was used for detecting different phases of the cell cycle 
(G0/G1, S, G2/M) and apoptotic (A) and necrotic (N) population. A representative 
flow cytometric file from Day 5 of culture is shown.  (B) Down-regulation of anti-
apoptotic genes by Lxn overexpression. Apoptosis PCR arrays were performed 
on A20 cells infected with empty or Lxn-expressing vectors. Left panel shows the 
fold changes in the mRNA expression of several selected genes (as indicated in 
X axis) in Lxn-overexpressing cells compared to the control. Western blot 
confirms the decreased expression of Bcl-2 and two isoforms of Pim-2 at the 
protein level in Lxn-overexpressing cells (arrowhead).  The other apoptosis-
related genes, such as Bcl-xl, Bax and Bad, did not show significant difference in 
mRNA and protein expression. (C) The growth curve of A20 cells treated with 
graded doses of potato carboxypeptidase inhibitor (PCPI). No significant 
difference is detected between the control and any of the doses of PCPI. (D) 
Internalization of PCPI to cytosol of A20 cells. A20 cells were cultured with 
fluorescein isothiocyanate (FITC) labeled PCPI. Shown is a three-color 
micrograph with PCPI in green (FITC), the B220 lymphoid cell surface marker in 
red (phycoerythrin, PE), the nucleus in blue (DAPI), and merged image of red 
and green as indicated.  
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Figure 5.5. Decreased Lxn expression in stem/progenitor-enriched CD34+ 
cells in patients with leukemia and lymphoma. 
 (A) Lxn mRNA expression in bone marrow and peripheral blood CD34+ cells 
from leukemia and lymphoma patients and normal individuals. Lxn mRNA level 
was measured by quantitative real-time PCR and shown as mean (± 1 SD) 
(n=12). Normal samples were derived from cord blood (CB), bone marrow (BM) 
of young at 31 (Y1) and 39 (Y2) years old and old at 85 (O1) and 97 (O2) years 
old people. The patient samples include acute myeloid leukemia (AML), T cell 
pro-lympho leukemia (Pctl), plasma cell leukemia (PCL), acute T cell lymphoma 
(ATLL) and acute lymphoid leukemia (ALL, preB phenotype). (B) LXN protein 
expression in bone marrow and peripheral blood CD34+ cells from leukemia and 
lymphoma patients and normal individuals. Western blot was performed on the 
corresponding samples shown in panel (A) plus five more samples, including two 
young (Y3 and Y4; at 40 and 31 years old respectively), two old (O3 and O4; at 
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80 and 87 years old respectively) and chronic myeloid leukemia (CML). The blots 
(bottom) and their quantification (top) profiles demonstrate the significantly 
decreased Lxn protein level in leukemic CD34+ and lymphoma cells (P=0.03). 
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Figure 5.6 Cpa3 is not expressed in A20 cells.  
Real-time PCR was performed on A20 cells that were either uninfected (A20 
control) or infected with empty (vector control) or Lxn expression vector (Lxn 
vector) to quantify Cpa3 mRNA expression. The amplification plots for Lxn (A), 
Cpa3 (B) and Gapdh (C) transcript show that Lxn is highly expressed in A20 cells 
infected with Lxn expression vector whereas A20 and vector controls have very 
low expression levels, consistent with the results in Fig. 5.3c. Cpa3 transcript is 
not amplified in all types of cells, indicating it is not expressed in A20 cells. These 
figures show the amplification plots of four individual biological replicates (n=4) 
for each gene.  
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Table 5.1 Carboxypeptidase A3 (Cpa3) is highly expressed in 
stem/progenitor cells. 
Probeset 1418625_s_at 1448730_at 1453770_at 1427995_at 1440617_at 
Gene Title 
 
glyceraldehyde-
3-phosphate 
dehydrogenase  
carboxy-
peptidase 
A3, mast 
cell 
carboxy-
peptidase 
A4 
carboxy-
peptidase 
A5 
carboxy-
peptidase 
A6 
Gene Symbol GAPDH Cpa3 Cpa4 Cpa5 Cpa6 
Chromosomal 
Location 6 C 59.3cM 
3 A2|3 13.2 
cM 6 A3.3 6 A3.3 1 A2 
Entrez Gene 14433 12873 71791 74649 329093 
mean_y_B6 11982.87 391.33 20.43 16.17 11.43 
GO Biological 
Process 
Description 
glucose 
metabolism /// 
glycolysis 
proteolysis 
and 
peptidolysis 
proteolysis 
and 
peptidolysis 
proteolysis 
and 
peptidolysis 
proteolysis 
and 
peptidolysis 
GO Cellular 
Component 
Description 
cytoplasm /// 
mitochondrion 
extracellular 
space 
extracellular 
space --- --- 
Expression level of CPAs were measured by microarray on a bone marrow 
population null for cell markers characteristic of lineage-specific differentiated 
blood cells (Lin-negative), and positive for the Sca-1 and c-Kit cell markers (LSK) 
cells, enriched for hematopoietic stem/progenitor cells in mouse. The isolation of 
LSK cells as well as microarray analysis was performed as previously described 
158 except the array platform is mouse Genome 430 2.0 Array (Affymetrix). Three 
biological samples were assayed, and the mean expression value (mean_y_B6) 
for each gene in the table is the average of three readings. Cpa3 (highlighted in 
gray) is the only Cpa gene that is highly enriched in LSK cells. Gapdh is the 
endogenous control.                
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                       CHAPTER 6: General Discussion and Conclusions 
Adult stem cells in a variety of organs are responsible for replenishing 
short-lived, mature cells as they become senescent. The proliferative and 
regenerative capacities of adult stem cells make them ideal therapeutic tools for 
treating the degenerative diseases and severe stresses such as tissue injury or 
prevention of infection.  
Our lab has uncovered novel features of adult hematopoietic stem cells, 
by implementing a forward genetic approach. Using this approach, our lab has 
identified several genes affecting stem cell population size and aging by 
correlating phenotypic variation to genotypic variation. Recent studies in our lab 
have demonstrated that endogenous stem cell numbers in young C57BL/6 (B6) 
and DBA/2(D2) mice are regulated by several candidate genes including Lxn93, 
Slit2 and p107 (manuscript in preparation). We learned that Lxn regulates 
hematopoietic stem cell pool size through balancing apoptosis, proliferation and 
self-renewal93. The studies outlined in this dissertation were designed to further 
elucidate the functions of Lxn in regulating hematopoietic stem cell biology. To 
serve this purpose, we generated a constitutive knockout mouse model in which 
the Lxn gene was ablated in the entire organism. Several biological features 
were analyzed in the Lxn null mouse model: First, I studied the phenotypes of 
Lxn null cells in peripheral blood, spleen and bone marrow. A hyperproliferative 
hematopoiesis was found in Lxn-/- mice. Experiments using an apoptotic marker 
identified decreased apoptotic frequency in Lxn-/- BM cells. Thus, I hypothesize 
that decreased apoptotic frequency was the primary mechanism underlying the 
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expanded leukocytes and BM progenitor cell population in Lxn-/- mice (see in 
chapter 2). Next, I explored the function of Lxn under genotoxic stress using 
ionizing radiation as the stressor. Ionizing radiation breaks chemical bonds, 
produce free radicals, and causes DNA damages167. DNA repair machinery is 
triggered to amend the DNA damage; however, when the damage is too severe 
to repair, apoptotic mechanisms are used to eliminate the damaged cells118. 
Apoptosis is beneficial to retain chromosome integrity, but can also induce 
cytopenia in hematopoiesis118.  Pro-apoptotic genes such as p53 and Puma are 
common pharmaceutical targets for treating radiation exposure because reduced 
apoptotic activities accelerate hematological and immune recoveries168-173. In the 
current studies, I found that Lxn-/- mice were more resistant to lethal and sub-
lethal doses of radiation due to greatly accelerated hematological and immune 
recoveries at one to six weeks after radiation50. The recovery advantage was 
resulted from a reduction in apoptosis in stem and progenitor cell populations 
(see in chapter 3). In another set of experiments, I studied the tumor suppressor 
function of Lxn by overexpressing Lxn in B cell lymphoma cells. The 
overexpression of Lxn up-regulated apoptotic frequencies in the lymphoma 
cells107. High levels of Lxn inhibited tumor formation by these cells in vivo and 
hindered tumor cell growth in vitro by inducing apoptosis (see in chapter 5)107. 
From the studies described above, I hypothesize that Lxn negatively regulates 
homeostatic cell expansion and radio-sensitivity of hematopoietic cells, and 
suppresses hematological malignancies by mediating apoptosis. Lxn expression 
levels are positively correlated with apoptotic activity (Fig. 6.1): High levels of Lxn 
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increase apoptotic frequency in tumor cells and therefore inhibit tumor cell growth. 
The down-regulation or absence of Lxn expression decreases apoptotic 
frequency in the peripheral blood and BM leading to a proliferative hematopoiesis. 
Loss of Lxn also confers radio-resistance by decreasing apoptotic frequency (Fig. 
6.1). Thus, Lxn is an important mediator in response to hematological stresses, 
and a potential recovery treatment for chemotherapy, radio-therapy and 
hemorrhage.  
As described above, apoptosis is one of the major mechanisms that 
eliminates undesired and cancer-prone cells. However, a novel role of apoptosis 
in controlling stem progenitor cell numbers and effecting stem cell-dependent 
regeneration has been identified by Elaine Fuchs and Hermann Steller's group in 
hair follicle stem cells. They found that mice deficient for a pro-apoptotic gene 
Sept4/ARTS have elevated numbers of hair follicle stem cells and remarkable 
improvement in wound healing and regeneration of hair follicles174. Our Lxn 
deficient mice an advantage in hematopoietic regeneration after severe oxidative 
stress (radiation) or after stem cell transplantation. There may be due to elevated 
apoptosis in stem and progenitor cells by loss of Lxn as a pro-apoptotic regulator. 
My studies did not definitively uncover the downstream signaling pathways 
which underlie the altered apoptotic frequencies in Lxn-/- mice or in cancer cells 
with Lxn overexpression. Two anti-apoptotic genes, Bcl-2 and Pim-2107, were 
significantly down-regulated in murine lymphoma cells with Lxn overexpression. 
Apoptosis is controlled by a balance between positive (pro-apoptotic) and 
negative (anti-apoptotic) signals124. Decreased levels of Bcl-2 allow other pro-
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apoptotic proteins to aggregate, therefore, inducing apoptosis107.  The tumor 
suppressor p53 is a negative regulator of Bcl-2 and the p53 signaling pathway is 
central in ionizing radiation-induced apoptosis125, 126. It is possible that the 
mechanisms underlying Lxn induced-programmed cell death are involved in p53 
and Bcl-2 mediated apoptotic signaling pathways.  
Another potential candidate involved in Lxn induced-apoptosis is Thbs-1. I 
found that the expression level of Thbs-1 was decreased in the Lxn-/- multipotent 
progenitor cell population, in which the absolute number of cells increased 
significantly (see in chapter 2). Thbs-1 null mice display a radio-resistance, 
similar to what I observed in Lxn-/- mice130. Further, it has been reported that 
Thbs-1 is involved in regulating radiation-induced apoptosis through a CD47-
mediated signaling pathway112, 117. To test this hypothesis, I will overexpress 
Thbs-1 in Lxn-/- HSCs and transplant them into lethally irradiation recipients. 
Three to four months post transplantation (when hematopoiesis is fully 
reconstituted), the radio-resistance of the recipients will be examined. If, as I 
hypothesize, overexpressing Thbs-1 in Lxn-/- cells will cause them to lose their 
recovery advantage and become more sensitive to radiation exposure due to an 
increased apoptotic frequency compared to empty vector transduced Lxn-/- cells.  
In a final set of experiments, I demonstrated the effects of Lxn on HSC 
migration activities and identified potential target gene(s) of Lxn that may 
regulate HSPC mobilization (see in chapter 4). As described above, Thbs-1 is 
down-regulated in the MPP population in Lxn-/- mice. Thbs-1 is an adhesive 
glycoprotein that mediates cell-to-cell and cell-to-ECM adhesions. It binds to 
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various adhesive molecules including fibrinogen, fibronectin, intergrin and 
collagen10. It is possible that Thbs-1 mediates BM cell retention and mobilization, 
and further regulates MPP cell numbers by influencing stem cell trafficking and 
localization.  
In conclusion, although yet far away from clinical application, my studies in 
this dissertation have identified various novel functions of Lxn including inducing 
proliferative hematopoiesis, responding to hematopoietic stresses, mediating 
tumor formation, and regulating stem cell and progenitor mobilization. My studies 
described the phenotypes of Lxn deficient animals; however, the mechanisms 
and signaling pathways underlying these phenotypes have yet to be definitively 
undetermined. In future experiments, I will study Lxn downstream signaling 
pathways, focusing on the potential target genes of Lxn identified by microarray 
analysis. I will examine the RNA expression profiles of candidate genes along the 
developmental hierarchy, and determine the effects of Thbs-1 overexpression in 
stem and progenitor cells using a retroviral vector. I hypothesize that performing 
CAFC assays with Lxn-/- cells in which Thbs-1 is overexpressed will result in 
decreased frequency of the primitive day 35 or later CAFC progenitor population. 
Further, I speculate that overexpressing Thbs-1 in Lxn-/- cells will lead to 
increased adhesion to stromal cells. 
Ultimately, I would like to translate these findings in the mouse to the 
treatments for human hematopoietic disorder. I hope these studies will aid in the 
clinical practice of hematopoietic cell expansion in which expanded cells may be 
used for accelerating hematologic and immunologic recoveries in patients 
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exposed to high energy radiation, as well as in transplantation procedures for the 
treatment of hematologic malignancies. My studies also discovered a novel role 
for Lxn as a putative tumor suppressor gene. This role of Lxn could be used in 
treatments designed to suppress the tumor cell growth and tumor formation in 
hematologic diseases. The potential roles of Lxn in clinical and pharmaceutical 
applications call for a detailed examination of the signaling pathways and 
downstream regulators of the gene. For example, agonists of the Lxn signaling 
pathway (which may stimulate downstream partners of Lxn) may promote 
apoptosis in cancer cells; whereas antagonists (which block the Lxn signaling 
pathway) may be utilized in expanding hematopoietic progenitor cells for 
radiation victims, or facilitating hematopoietic reconstitution following stem cell 
transplantation. The treatments of hematologic disorders using stem cell 
therapies have advanced greatly in recent years. In this dissertation, I studied 
various functions of Lxn in hopes of aiding the development of such therapies.  
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Figure 6.1 Mechanisms of Lxn in influencing hematopoietic biology 
through regulating apoptosis.  
The expression of Lxn is positively correlated with apoptotic activities. Elevated 
expression levels of Lxn increase apoptotic frequency in tumor cells and inhibit 
tumor cell growth both in vitro and in vivo. Down-regulation of Lxn decreases 
apoptotic frequencies in the peripheral blood and BM and results in a proliferative 
hematopoiesis under homeostatic condition in Lxn-/- mice. Loss of Lxn 
expression also confers a radio-resistance to Lxn-/- mice by decreasing 
radiation-induced apoptosis.  
 
 
 
 
 
 
 
 
151 
APPENDIX 
Abbreviations 
ALL Acute lymphoid leukemia 
AML Acute myeloid leukemia 
ATLL Acute T cell lymphoma 
B6 C57BL/6 mouse 
BM Bone marrow 
BrdU 5-bromo-2-deoxyuridine 
CAFC Cobblestone-forming cell assay 
CB Cord blood 
CFU Colony-forming cell unit 
CLP Common lymphoid progenitor 
CMP Common myeloid progenitor 
CPA Carboxypeptidase A 
CR Competitive repopulation 
ECM Extracellular matrix 
FBS Fetal bovine serum 
G-CSF Granulocyte-colony stimulating factor 
Gfm-1 G-elongation factor, mitochondria-1 
GMP Granulocyte/monocyte progenitor 
HPC Hematopoietic progenitor cell 
HSC Hematopoietic stem cell 
HSPC Hematopoietic stem and progenitor cell 
LK Lineage-c-Kit+ 
LS Lineage-Sca-1+ 
LSK Lineage-c-Kit+Sca-1+ 
LT-HSC Long term-hematopoietic stem cell 
Lxn Latexin 
MEP Megakaryocyte/erythroid progenitor 
MPP Multipotent progenitor 
PBS Phosphate buffered saline 
PCPI Potato carboxypeptidase inhibitor 
PGE2 Prostaglandin E2 
PI Propidium iodide 
PSGL-1 P-selectin glycoprotein ligand-1 
PTH Parathyroid hormone 
SCF Stem cell factor 
SDF-1 Stromal derived factor-1 
SP Side population 
ST-HSC Short term-hematopoietic stem cell 
T-PLL T cell pro-lymphocytic leukemia 
TBI Total body irradiation 
TIG-1 Tazarotene-induced gene1 
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